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LIST OF COMMONLY 
USED ABBREVIATIONS 
BHR Bronchial hyper-responsiveness 
Der f Dermatophagoides farinae 
Der p Dermatophagoides pteronyssinus  
GWAS Genome wide association study  
HWE Hardy-Weinberg equilibrium 
IFN Interferon 
IgE Immunoglobulin E 
IL Interleukin 
ISAAC The International Study of Asthma and Allergies in Childhood 
LD Linkage disequilibrium 
OR Odds ratio 
PAMP Pathogen-associated molecular pattern  
PIA Pro-inflammatory allele 
SNP Single nucleotide polymorphism 
SPT Skin prick test 
STR Short tandem repeat 
TH0 Naïve T helper lymphocytes 
TH1 Type 1 T helper lymphocytes (and their cytokines)  
TH2 Type 2 T helper lymphocytes (and their cytokines)  
TLR Toll-like receptor 
TNF Tumour necrosis factor 
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INTRODUCTION 
As the burden of infectious diseases around the world has gradually decreased 
over the past 25 years (Lozano et al. 2012), increasing attention is being paid 
to non- communicable diseases. Asthma and allergies are being globally 
recognised as major public health problems (Baena-Cagnani 2001). 
Conservative estimates suggest that about 500 million people globally suffer 
from allergic rhinitis, and about 300 million people suffer from asthma (Masoli 
et al. 2004; Ozdoganoglu & Songu, 2012). Locally, the burden of allergic 
disease is thought to be increasing (Weinberg 2000; Zar et al. 2007), and there 
is concern locally and globally that regions and countries with poor 
socioeconomic conditions may have disproportionate morbidity and mortality 
from asthma and other allergies (Poyser et al. 2002). Of particular concern is 
the pattern of increased prevalence of allergic conditions associated with 
urbanization and adoption of a western lifestyle, in combination with increased 
morbidity and mortality associated with poor socioeconomic status (Poyser et 
al. 2002), meaning that the recently urbanized poor disproportionately bear the 
brunt of the allergy epidemic. 
South Africa is acutely affected by asthma and allergic diseases. Our rates of 
urbanization (United Nations Department of Economic and Social Affairs 
Population Division (2014)) mean that our urban poor population is continuing 
to expand. Public health still faces the obstacles of poverty, systemic inequality 
and relatively poor access to health care. Data suggests that the prevalence of 
allergic disease is high, and still increasing (Zar et al. 2007), and that asthma 
mortality is disproportionately high (Masoli et al. 2004). 
Globally, tremendous strides are being made in the study of allergic diseases. 
This progress has been largely spearheaded by a revolution in our 
understanding of the human genome, coupled with new technology that has 
made rapid and cost-effective genome sequencing a reality. Technological 
advances in the fields of immunology and histology have improved our ability 
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to elucidate clinical phenotypes, and improved statistical analysis has improved 
the quality of data obtained from research. Increasing understanding of the 
genetic, pathophysiologic and histologic bases of asthma and allergies may, 
in time, help us to improve the treatment (Barnes 2010), and possibly even 
prevention of allergic disease. Nonetheless, several important questions still 
remain, including the following. Why is the prevalence of allergy increasing in 
some countries, plateauing in some, and decreasing in others? What are the root 
genetic and environmental causes of asthma and allergies? What is the precise 
quantity and quality of the genetic contribution to the development of allergic 
disease? On what basis are the apparent differences in prevalence and severity 
of allergic disease on the basis of socioeconomic status, ethnicity and 
geographic location? 
One of the hypotheses for the difference in prevalence of genetic markers 
associated with allergic disease is that of evolutionary adaptation of the 
immune system (Le Souëf et al. 2006). The assertion is that modern man’s 
origins in a tropical environment conferred a survival advantage upon people 
who had an immune system primed to combat helminths and other parasitic 
illnesses (Le Souëf et al. 2000; Le Souëf et al. 2006). Our migration to more 
temperate climates has made the adverse effects (including allergic disease) of 
this priming outweigh the benefits (Le Souëf et al. 2000). To date, there has 
been no data published with the specific aim of interrogating this hypothesis. 
Our study is primarily concerned with the relationship between genetics and 
allergic disease in a Black African (Xhosa) population. We feel that this is an 
important topic for many reasons. Firstly, we know from high quality studies 
(Van Niekerk et al. 1979; Ehrlich et al. 1995; Zar et al. 2007) that the prevalence 
of allergic disease is increasing in South Africa, specifically amongst Xhosa 
people. Secondly, there is very little data either locally or globally on the 
genetic determinants of asthma and allergies in populations who are not of 
Caucasian origin (Barnes et al. 2007). There is currently insufficient evidence 
to know whether the genetic determinants of allergic diseases are similar in 
people of different ethnicities, and there are examples in the local literature to 
suggest that allergic phenotypes (Abbott et al. 2013) and genotypes (Thawer-
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Esmail et al. 2014) may not be the same as in the developed world. 
Our study aims to examine the prevalence of alleles thought to promote allergic 
disease. We also aim to examine the relationship between these alleles and 
clinical and laboratory features of asthma and allergies. It is the first time that 
the relationship between many of the alleles and allergic disease is being 
studied in a Black African population. We therefore hope that our study will 
be a significant contribution to the local literature regarding the genetic 
aetiology of allergic disease. Until recently, the cost of performing genotyping 
was almost prohibitive in the developing world. This is rapidly changing, and 
the possibility of performing genotyping across hundreds of thousands of 
polymorphisms throughout the genome in the search for disease associations 
may become a reality even in resource constrained settings. This study 
currently represents the first in South Africa to examine the relationship 
between such a variety of genetic polymorphisms and allergic disease. 
Our investigation involves a cross-sectional study of just over 200 Xhosa 
adolescents from a high school in Cape Town, South Africa. After informed 
consent was obtained, blood was drawn for genotyping, and further testing was 
performed including administering a questionnaire on personal history of 
asthma and allergies, skin prick testing for allergic sensitization to common 
aero- and food allergens, and blood total and Ascaris-specific IgE levels. This 
has enabled us to measure allele frequencies in this population, as well as to 
compare individual genotypes and allergic phenotypes in our sample. Several 
articles have been published by our group that report on the phenotypic 
characteristics of the sample population. These articles have focussed on the 
relationship between asthma and bronchial hyper-responsiveness (BHR) with 
allergy and atopy phenotypes (Levin et al. 2011), the influence of atopy and 
Ascaris sensitization on serum IgE levels (Levin et al. 2008) and the association 
between Ascaris sensitization and asthma and allergy phenotypes (Levin et al. 
2012). However, until now, the prevalence of potential pro-inflammatory 
alleles (PIAs), as well as correlations between genotype and phenotype, has not 
been interrogated in this sample. This thesis represents the first, and only 
analysis of the genetic data obtained from this sample. 
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We hope that this study will be useful in guiding further research into the 
genetics of allergic disease in South Africa. In addition, our data forms part of 
a collaborative dataset from several countries around the world that aims to 
investigate the possibility of evolutionary adaptation of the immune system as 
an explanation for differences in allele prevalence between population groups 
(Le Souëf, personal correspondence). This data may contribute to the 
international literature in helping to better understand the impact of evolution 
and ethnicity on allergic disease. 
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The term ‘allergy’ was coined in the early 20th century by Viennese 
paediatrician Clemens von Pirquet Freiher (Igea 2013). At the time, the 
concept was meant to convey the idea that the first contact of the immune 
system with an antigen changes the way the body reacts to that antigen, such 
that on subsequent contacts, this change could induce a spectrum of responses, 
from protective to harmful (Igea 2013). 
Much has changed since the term was proposed slightly over a century ago. 
Our understanding of the structure and function of the immune system has 
improved exponentially, we have a vastly more accurate idea of the basic 
pathophysiological mechanisms of allergy, and the contributions of genetics 
and environment and their impact on allergic disease have received significant 
recent attention. The last thirty years have witnessed explosive advances in the 
field of human genetics, and in conjunction with massive strides in 
immunology and statistical analysis, we are much closer than before to 
illuminating the root causes of allergic disease. 
That being said, there are still many questions with regards to the pathogenesis, 
pathophysiological mechanisms, and contributions of genetic and 
environmental aetiologies in the causation of allergic disease. As with many 
other health care problems, there is still massive inequality in the field of 
allergy, both in terms of research and health outcomes. The magnitude of this 
inequality is beginning to be considered in South Africa (Green et al. 2007) 
and globally (Beran et al. 2015). 
Our study forms the South African arm of a global study looking at the genetic 
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effects of ethnic origins on asthma and allergies. Our study population is a 
group of Xhosa teenagers, who as Black Africans, represent an understudied 
sector of the global society. We hope this study will contribute significantly to 
the local and, possibly, international literature in helping to identify genetic 
markers that are associated with allergic disease in this population group. 
In reviewing the literature relevant to our study, I will therefore consider the 
pathogenesis and pathophysiology of allergic disease, the burden of allergic 
disease globally and in South Africa, before discussing the current state of 
genetic research  in allergic disease. I will highlight the gaps in research that 
our study is hoping, in part, to fill, and give background in respect of the 
specific genes and polymorphisms of relevance to our investigation. 
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PATHOGENESIS AND PATHOPHYSIOLOGY 
OF ALLERGIC DISEASE 
Perhaps the key attribute of the immune system is the ability to discern self 
molecules from potentially harmful non-self molecules (Chinen et al. 2009). 
The immune system exists in a balance between self-tolerance and response 
to, or rejection of, non-self (Chinen et al. 2009). The typical allergic response 
involves an abnormal immune response to an inert molecule, usually an 
environmental protein (Eisenbarth 2006). Much research in allergy is devoted 
to answering why and how the immune system reacts to these essentially 
harmless triggers (Eisenbarth 2006). 
The human immune system is made up of two complementary systems, the 
innate and adaptive immune systems (Chinen et al. 2009). The innate immune 
system provides rapid, non-specific responses based on recognition of 
microbial patterns not found in the host (Chinen et al. 2009), whereas the 
adaptive immune system enables recognition of specific pathogens and 
amplification of an appropriate and specific response to that pathogen (Chinen 
et al. 2009). Although much focus has been  placed on the adaptive immune 
system (and TH2 responses in particular), adaptive T lymphocyte responses 
require priming from the innate immune system (Eisenbarth 2006), meaning 
that alterations in both innate and adaptive immunity may play a role in the 
development of allergies. 
Although allergic disease may present in many guises, a common pattern of 
inflammation is seen in most, and is often driven by IgE-dependent 
mechanisms (Barnes 2011). As this study is primarily interested in IgE-
mediated allergic disease, the pathophysiology of IgE-mediated inflammation 
will form the focus of this review. However it is worthwhile to mention that a 
number of allergic responses are recognized as being either non IgE-mediated 
or mixed IgE- and non IgE-mediated reactions. It is hoped that an improved 
understanding of the mechanisms of causation of allergic disease will lead to 
improved methods of treatment or even prevention. 
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Mechanism of Allergic Inflammation 
The allergic immune response has evolved from our inflammatory response to 
worm and parasite infestations (Barnes 2011). Central to most forms of allergic 
inflammation is TH2 lymphocyte orchestrated activation of mast cells, with 
subsequent release of inflammatory mediators and influx of eosinophils and 
other inflammatory cells (Barnes 2011). 
An allergic immune response occurs when B lymphocytes produce large 
quantities  of allergen-specific IgE (Barnes 2011). This IgE then coats the 
surface of mast cells, the Fc portion of the IgE bonding to the high-affinity IgE 
receptor (FcεRI) on the mast cell membrane (Amin 2012). Subsequent 
exposure to the same allergen induces allergen binding to the Fab portion of 
the cell-bound IgE, and the resulting cross- linking triggers release of pre-
formed mediators (prostaglandins, histamine and other mediators), in a process 
known as degranulation, as well as production of new mediators (leukotrienes, 
prostaglandin D2, and interleukins 4, 5 and 13, amongst others) (Amin 2012). 
The cumulative effect of this mediator release includes  increase in endothelial 
permeability, activation and chemoattraction of other inflammatory cells, 
induction of immunoglobulin class switching of B lymphocytes to produce 
more IgE, as well as potentially having a direct effect on airway damage and 
remodelling in asthma (Amin 2012). 
Although the pathophysiology of the allergic response is fairly well studied, 
we still do not fully understand what primes the immune system to produce a 
vigorous TH2 response to essentially inert molecules. Emerging evidence 
suggests that the innate and adaptive immune systems, working in concert, are 
able to induce three major types of response to pathogens (Annunziato et al. 
2014). A type 1 immune response involves TC1 cytotoxic lymphocytes, TH1 
lymphocytes and IFN-γ producing innate lymphoid cells (ILCs), and is largely 
concerned with protection against intracellular pathogens through phagocyte 
activation (Annunziato et al. 2014). Type 2 responses involve TC2 cytotoxic 
lymphocytes, TH2 lymphocytes and GATA-3 ILCs, and produce IL-4, IL-5 and 
IL-13, inducing mast cell, eosinophil and basophil activation (Annunziato et 
al. 2014). Type 2 immune responses protect against helminths and venoms, 
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largely through specific IgE antibody production (Annunziato et al. 2014). 
Type 3 immune responses involve TC17 and TH17 lymphocytes as well as 
ILC3s, producing IL-17 and/or IL-22. This results in phagocyte activation, 
neutrophil recruitment and induction of epithelial antimicrobial responses, 
protecting against extracellular organisms like bacteria and fungi (Annunziato 
et al. 2014). Traditionally, it has been held that allergy results from an 
inadvertent activation of a type 2 immune response by an innocuous molecule, 
but recent research has highlighted the role of the type 2 immune response in 
response to toxins such as venom, and raised the possibility that allergens are 
not as innocuous as believed (Annunziato et al. 2014). 
Not surprisingly, much attention has been directed towards the factors leading 
to the differentiation of the immune system towards the type 2 response. IL-4 
is the main differentiation factor for TH2 lymphocytes (Eisenbarth 2006), and 
the IL-4 pathway, including the molecule itself, its receptors, IL-13 (which 
shares many effects with IL-4 (Luzina et al. 2012)) and its signalling pathway 
(including STAT6) has been the focus of much interest. Recent research (Wan 
2014) has suggested GATA3 as the ‘master factor’ in TH2 differentiation, 
although no research has yet compellingly linked the GATA3 gene with 
allergic disease (Li et al. 2006; Suttner et al. 2009). Its signalling pathways, 
co-factors and other elements of its function remain to be fully discerned (Wan 
2014; Yagi et al. 2011). 
Microbial Influence 
Since the recognition, over sixty years ago, that number of siblings (especially 
older siblings) is a protective factor in the development of hay fever (Strachan 
1989), it  has been plausible that exposure to microbial products can influence 
the character of the human immune response to antigen. Further studies have 
demonstrated that exposure to pets, microbes and dust from farm environments 
are also protective against the development of allergy, whilst exposures such 
as urban environments, small families, birth via caesarean section and maternal 
antibiotic use in pregnancy are promoting factors (Daley 2014). The ‘hygiene 
18
 
hypothesis’ is a concept initially developed (Strachan 1989) as a means to 
explain why asthma and allergies were increasing rapidly in the industrialized 
world at the time (Daley 2014). The author theorized that early life exposure 
to viral and bacterial organisms influences how the immune system responses 
to further stimuli, and that elimination of these exposures results in a shift in 
immune response that promotes the formation of asthma and allergies (Daley 
2014). The theory was advanced to suggest that the mechanism of this shift 
was through persistence of the TH2 predominance in the immune system seen 
in perinatal cytokine profiles (Daley 2014). 
 
Lipopolysaccharide (LPS), and endotoxin (its bioactive moiety), have been 
extensively studied in relation to their impact on immune responses (Simpson 
& Martinez 2010). LPS is a component of gram-negative bacterial outer 
membranes (Simpson & Martinez 2010), and is common to all gram-negative 
bacteria, making it an archetypal pathogen-associated molecular pattern 
(PAMP) (Simpson & Martinez 2010; Vercelli 2002). The evidence for the role 
of endotoxin in the formation of allergies has been contradictory. Exposure to 
endotoxin in early life has shown to be protective against allergy and asthma 
formation (von Mutius et al. 2000), but in certain settings, exposure to 
endotoxin has been shown to induce a potent inflammatory response that 
includes bronchospasm as one of its symptoms (Simpson & Martinez 2010). It 
is possible that the timing, level of exposure, environmental setting and genetic 
susceptibility all play a role in the response of the immune system to endotoxin 
(Simpson & Martinez 2010). 
 
The role of viral infections, particularly rhinovirus-c (hRV-c) and respiratory 
syncytial virus (RSV) (Holt et al. 2012), in the development of asthma, has 
attracted much recent interest. There is accumulating evidence that viral 
infections in infancy and pre-school years is strongly associated with the 
development of asthma (Holt et al. 2012; Holt 2015). It is postulated that the 
combination of viral infection and susceptibility to atopy results in alternative 
activation of myeloid precursors in the bone marrow, with replacement of 
airway mucosal dendritic cells by cells primed towards TH2 activation (Holt et 
al. 2012). This may, in part, be responsible for the incorporation of TH2 
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inflammatory cells and cytokines into the inflammatory milieu of the airways 
(Holt et al. 2012). 
 
Perinatal Factors 
It has been hypothesised that a child’s environmental surroundings in the first 
1000 days post-conception greatly influence the development of chronic 
disease (Wegienka et al. 2015). There is a gradual accumulation of evidence to 
support this hypothesis with regards to asthma and allergic disease (Wegienka 
et al. 2015). In a recent review, Holt (2015) discusses the evidence for in-utero 
priming on the immune system, including the discovery of apparently aero-
allergen specific TH2 cells in cord blood, although he notes that this evidence 
has subsequently been called into question. 
 
Much interest remains in the relationship between early life influences, and the 
subsequent development of allergies. The microbial organisms that we harbour 
and interact with on a daily basis are collectively referred to as the microbiome 
(Wegienka et al. 2015), and there is increasing interest in how the neonatal and 
infant microbiome impacts on the predisposition towards disease. Mode of 
delivery, choice of feed and duration of breastfeeding, exposure to household 
pets, exposure to environmental pollutants, and antibiotic use (either maternal 
use during pregnancy or infant use in the first two years of life) are all thought 
to influence the formation  of the microbiome (Wegienka et al. 2015). The 
association of faecal composition at one month of age, and the subsequent 
development of atopy was highlighted in the KOALA study (Penders et al. 
2007), which found that the presence of E.coli in the stool was associated with 
atopic eczema, whereas the presence of C.difficile was associated with atopic 
eczema as well as recurrent wheeze and allergic sensitisation. Recent evidence 
from the Canadian Healthy Infant Longitudinal Development (CHILD) study 
(Arrieta et al. 2015) has shown that infants at risk of asthma exhibit transient 
gut dysbiosis during the first one hundred days of life, and that the abundance 
of 4 bacteria (Lachnospira, Veillonella, Faecalibacterium, and Rothia) was 
significantly decreased in children at risk of asthma. This supports the 
hypothesis that dysbiosis in early life is associated with the development of 
allergic disease, and shows the potential for possible microbe-based 
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diagnostics and therapeutics in the future (Arrieta et al. 2015). 
 
Oral Tolerance 
The mucosa of the gastrointestinal tract is the largest body surface area exposed 
to the outside environment (van Wijk & Knippels 2007). Immediately after 
birth, it is confronted with a large amount of foreign antigen (van Wijk & 
Knippels 2007). The mucosal immune system, the largest component of the 
body’s immune system (Wopereis  et  al.  2014),  is  faced  with  the  task  of  
distinguishing  which  of these antigens are potentially pathogenic, and which 
are not harmful (van Wijk &  Knippels 2007). The fact that humans do not 
mount immune responses to many antigens, and that only a minority of people 
develop food allergies, is due to the induction of oral tolerance (Chehade & 
Mayer 2005). Oral tolerance refers to the process whereby immune responses 
to an antigen are actively inhibited by means of prior oral exposure to that 
antigen (Chehade & Mayer 2005). 
 
The human gastrointestinal tract is colonized by approximately ten times more 
microbial cells than human body cells (Wopereis et al. 2014). In addition, these 
microbial cells contain about 150 times more microbial genes than the human 
genome (Wopereis et al. 2014). Although the human genome is relatively 
fixed, the combined genetic information of intestinal microbiota is highly 
variable depending on which organisms colonise the gastrointestinal tract 
(Wopereis et al. 2014). Improved understanding of the maintenance of this, 
generally symbiotic, relationship between the mucosal immune system and the 
intestinal microbiota has allowed for modification of the ‘hygiene hypothesis’ 
model of understanding allergy. It has become clearer that colonisation of the 
gastrointestinal tract with the right microbes of sufficient biodiversity is 
protective against allergies (Daley 2014), and conversely that dysregulation of 
this healthy symbiosis between the immune system and intestinal 
microorganisms may be a key factor in allergy formation (Daley 2014). 
 
Factors that promote oral tolerance to an antigen include those related to both 
host and antigen (Chehade & Mayer 2005). Antigen factors include the dose 
and form of antigen, as well as the timing of exposure (Chehade & Mayer 
21
 
2005), whereas host factors include age, genetic makeup and composition of 
intestinal flora (Chehade & Mayer 2005). Many cells play a role in the 
development of tolerance, including regulatory T lymphocytes and dendritic 
cells (Chehade & Mayer 2005; Wopereis et al. 2014), and although further 
research needs to be done in delineating the exact pathways of oral tolerance 
on the one hand, and allergic sensitisation on the other, it would seem that a 
breach of any of the normal mechanisms by which the immune system 
encounters allergens may be sufficient to cause sensitisation (Chehade & 
Mayer 2005). 
 
Skin Barrier and Filaggrin 
The phenomenon of the progression of allergic disease, from atopic eczema in 
infancy, to allergic rhinitis and asthma in childhood, is well described. One of 
the first clinicians to appreciate this progression was Lorn Shore, a South 
African, who described children as ‘standing in the queue for asthma’ 
(Weinberg 2014). The term ‘atopic march’ has now been coined to describe 
this phenomenon, but its underlying mechanisms remain to be fully established 
(Suzuki et al. 2011). Immunohistological evidence suggests that an intact 
epidermal barrier protects the immune system from exposure to allergens that 
could potentially lead to allergic reactions (Suzuki et al. 2011), but until 
recently the precise mechanisms by which allergens could penetrate into the 
sub-epidermal layer of the skin were not known (Suzuki et al. 2011). The 
discovery of the Epidermal Differentiation Complex, and in particular the 
filaggrin gene (Palmer et al. 2006), on chromosome 1 as a risk factor not only 
for the development of atopic eczema, but also for the development of asthma 
and allergic rhinitis, was an important piece in the puzzle of the ‘atopic march’. 
 
Several studies (Palmer et al. 2006; Ekelund et al. 2008; Rice et al. 2008; 
Weidinger et al. 2008) have confirmed the importance of filaggrin gene 
mutations in the progression of allergic disease in Caucasian people, but this 
data has yet to be replicated in people of Black African origin (Thawer-Esmail 





The World Allergy Organization defines asthma as: “… a chronic 
inflammatory disorder of the airways associated with airway 
hyperresponsiveness and airflow obstruction that is often reversible either 
spontaneously or with treatment.” (Holgate et al. 2013). Although multiple 
clinical phenotypes exist, atopy (the predisposition to produce specific IgE 
antibodies to a potential allergen), remains the most common identifiable 
trigger (Holgate et al. 2013). Other identified triggers include genetic 
predisposition, environmental factors and likely alterations in the microbiome 
(Mims 2015), and are more fully described elsewhere in this review. Recently, 
increasing attention has been paid to the idea of asthma as a syndrome 
comprised of multiple clinical phenotypes (Agache et al. 2012; Haldar et al. 
2008), rather than as a single disease entity.  
 
Descriptions of different phenotypes is clinically useful in terms of disease 
presentation, triggers and response to treatment, but does not always provide 
information regarding precise pathophysiological mechanisms (Agache et al. 
2012), and there has been a lack of long term studies to assess the stability of 
specific phenotypes (Agache et al. 2012). Significant progress is also being 
made in endotyping asthma. Whilst phenotypes refer to separate clinical 
entities, endotypes represent subtypes of disease based on  specific 
pathophysiological mechanism (Skloot 2015). Improved understanding of 
asthma phenotypes and endotypes may assist in more accurate correlation with 
genetic susceptibility to disease (Giavina-Bianchi et al. 2013) and potentially 
allow for more personalised approaches to therapy (Skloot 2015). 
 
The core clinical features of asthma are airway inflammation, bronchial hyper- 
responsiveness and reversible airflow obstruction (Holgate & Sly 2014).  
Recruitment and activation of multiple cell types, including mast cells, 
eosinophils, basophils, neutrophils, dendritic cells, macrophages and T 
lymphocytes contribute to cellular infiltration into the airways (Linzer 2007). 
Cytokine and pre-formed  mediator release both contribute to the inflammatory 
infiltrate and perpetuate the cycle of inflammation through ongoing 
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recruitment and activation of inflammatory cells (Linzer 2007). T lymphocytes 
likely play an orchestrating role in the late allergy response, and contribute to 
airway remodelling (Mims 2015; Linzer 2007). 
 
The abnormal TH2 immune response, and in particular the increased expression 
of IL-13 within the lungs, initiates an aberrant airway repair process 
(Bonsignore et al. 2015). Some of the major effects of IL-13 include increased 
bronchial hyper- responsiveness (through the effects of inflammatory 
mediators on the local autonomic nervous system (Linzer 2007)), activation of 
fibroblasts and increased goblet cell differentiation (Bonsignore et al. 2015). 
The epithelium of the airway becomes fragile, and thickening of the basement 
membranes, in conjunction with increased production of mucous (as well as 
changes in mucous consistency) and endothelial leakage, lead to mucosal 
oedema (Linzer 2007). In the presence of chronic inflammation, these 
processes contribute to airway remodeling. 
 
Allergic Rhinitis 
Under normal conditions, the nasal mucosa efficiently warms, humidifies and 
cleans inspired air (Skoner 2001). In allergic rhinitis, the normal mechanisms 
that  contribute to this efficient process are derailed, leading to symptoms of 
watery rhinorrhoea, itch, nasal congestion and sneezing (Min 2010). 
 
The allergic rhinitis response can be divided into early and late phases. In the 
immediate phase, release of pre-formed and newly synthesised inflammatory 
mediators from mast cells cause mucosal oedema and watery rhinorrhoea 
(Skoner 2001). Glandular secretion of mucoglycoconjugates and antimicrobial 
compounds,  in addition to blood vessel dilatation leading to sinusoidal filling, 
result in occlusion and congestion of the nasal passages (Skoner 2001). The 
inflammatory mediators additionally stimulate sensory nerves to cause 
symptoms of itch and nasal congestion, and stimulate reflex responses such as 
sneezing (Skoner 2001). 
 
In contrast, the late response is characterised by eosinophil chemotaxis (Min 
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2010). Chemoattractants such as IL-5 contribute to the mucosal infiltration 
with  eosinophils, neutrophils, basophils, T lymphocytes, and macrophages 
(Skoner 2001). These cells become activated, and release inflammatory 
mediators, which in turn reactivate the pro-inflammatory cytokines of the 
immediate phase (Skoner 2001), leading to a cycle of ongoing inflammation. 
T lymphocytes, again, are the likely orchestrators of the process (Skoner 2001). 
In addition, priming of the allergic response results in both a decreased 
threshold for the quantity of allergen required to result in a response (Skoner 
2001), and in non-specific hyper-responsiveness, resulting in an ‘allergic’ 
response to non-allergen triggers in an IgE-independent manner (Min 2010). 
 
Atopic Eczema 
An intact epidermis is a prerequisite for skin to function as a normal physical 
and chemical barrier (Bieber 2008). Alteration of this barrier leads to 
transepidermal water loss, which is the hallmark of atopic eczema (Bieber 
2008). The central pathophysiological features of atopic eczema are chronic, 
relapsing skin inflammation and disturbance of the epidermal barrier function 
(Bieber 2008). The causes of these features are not yet fully understood, but 
evidence suggests a broad range of environmental modifiers affecting 
predominantly genetically susceptible individuals (Lyons et al. 2015). The 
changes described above lead to dry skin and, in some atopic eczema sufferers, 
IgE-mediated sensitisation to food, environmental, bacterial or even self-
antigens (Bieber 2008). 
 
Two hypotheses predominate regarding eczema formation. The first is that a 
primary defect in the epithelium leads to skin barrier dysfunction, with skin 
immune dysfunction occurring as an epiphenomenon. Alternatively, a primary 
disturbance in the local immune system may cause IgE-mediated sensitisation 
and inflammation, which then leads to barrier dysfunction (Bieber 2008; Kang 
& Stevens 2003). 
 
As a contribution to skin barrier dysfunction, mutations in the filaggrin gene 
have garnered much recent attention in the literature. Filaggrin contributes to 
the keratin cytoskeleton by acting as a template for the cornified envelope 
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(Bieber 2008; Lyons et al. 2015). In addition, filaggrin breakdown products 
contribute to the water  binding capacity of the epidermis (Bieber 2008). 
Genetic mutations in the filaggrin gene cause various changes in the functional 
product, leading to barrier dysfunction (Kang & Stevens 2003). In addition, 
skin inflammation can affect filaggrin expression (Bieber 2008). However, it 
appears that filaggrin gene mutations alone are insufficient to explain the 
development of atopic eczema in all patients.  Mutations are only present in 
about 30% of adult patients with atopic eczema in European studies (Bieber 
2008), and have not consistently been found in Black African populations 
(Thawer-Esmail et al. 2014). Mutations in the genes for other structural skin 
proteins may also be relevant in skin barrier dysfunction (Lyons et al. 2015). 
 
Epithelial cells exist at the interface of the skin and the environment, and thus 
are the first line of defence against environmental pathogens (Bieber 2008). 
They are equipped with several structures to detect microbes and their 
components, including toll-like receptors and C-type leptins (Bieber 2008), 
which, when activated, cause production of antimicrobial molecules such as 
defensins and cathelicidins (Bieber 2008). In atopic eczema, the inflammatory 
response initiated by, amongst others, IL- 4 and IL-13, downregulate these 
antimicrobial products (Bieber 2008; Lyons et al. 2015).    This  leads  to  
increased  susceptibility  to  colonisation  and  infection    by pathogens. More 
than 90% of atopic eczema patients are colonised by Staphylococcus aureus, 
which promotes ongoing inflammation through a variety of mechanisms (Kang 
& Stevens 2003), and contributes to topical corticosteroid resistance (Bieber 
2008). 
 
In patients with early-onset atopic eczema, skin lesions appear before IgE-
mediated sensitisation (Bieber 2008), leading us to believe that in these 
patients, the skin is the primary site of sensitisation. The skin contains double 
the number of T lymphocytes in comparison with the circulation (Bieber 
2008), which shows that severe skin inflammation is capable of affecting 
systemic adaptive immunity (Bieber 2008). In severe atopic eczema, IgE 
antibodies are formed not only against allergens, but also against skin proteins 





IgE-mediated Food Allergy 
Whilst this review has previously discussed the topic of oral tolerance, it is 
worthwhile re-iterating that the physical and immunologic components of the 
gastro- intestinal mucosal barrier are faced with the daunting task of processing 
ingested  food into an absorbable form, whilst simultaneously preventing 
pathogen penetration into the body (Sicherer & Sampson 2010). In addition, 
whilst the systemic immune system is generally confronted by small amounts 
of foreign antigens, and is able to mount a rapid inflammatory response, the 
mucosal immune system is regularly confronted with massive amounts of 
antigens, and must suppress or regulate immune responses to food and 
‘harmless’ commensal organisms (Sicherer & Sampson 2010). The inability to 
develop oral tolerance is thought to result from a combination of  host factors, 
the dose and timing of antigen exposure and the microbial micromilieu in 
which the exposure takes place, as well as certain specific properties of the 
allergens themselves (Vickery et al. 2011). 
 
The increased prevalence of food allergies in young children relative to adults 
suggests that immaturity of the mucosal barrier may be a factor in the 
development  of food allergies (Wang & Sampson 2009). Variation in the rates 
of susceptibility to allergens amongst different mouse strains also suggests that 
genetic predisposition to food allergy is likely (Wang & Sampson 2009). 
The intestinal immune system in young children is relatively immature, 
showing decreased expression of certain enzymes, and decreased functionality 
of the secretory IgA system (Sicherer & Sampson 2010) as examples. There is 
also some evidence that physical barrier properties may be deficient in children 
with food allergies. Studies have shown that decreases in gastric acidity are 
linked with higher sensitisation rates (Sicherer & Sampson 2010), and there is 
increasing evidence that any disturbance of the mucosal barrier may lead to 
increased susceptibility to food allergy (Wang & Sampson 2009). 
 
Mucosal immune responses to soluble proteins in early life tend to be TH2 
biased in both humans and other mammals (Vickery et al. 2011). There is some 
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evidence that genetic predisposition leads to an exaggeration of this bias 
(Vickery et al. 2011), but evidence also suggests that IgE antibodies to egg, 
milk and peanut occur commonly, even in healthy infants (Vickery et al. 2011). 
In healthy infants, this TH2 weighted response seems to be transient, with IgE 
levels falling over time, in contrast to the persistence seen in allergic children 
(Vickery et al. 2011). The immune response to foreign antigens also seems to 
differ, at least in part, on the dose of exposure. The response to high-dose 
exposure involves deletion of effector T lymphocytes, whereas low-dose 
exposure results in activation of regulatory T cells, with suppressor functions 
(Sicherer & Sampson 2010). Although gut immaturity is thought to be a factor 
in the development of food allergy, exposure in the correct context may be 
beneficial at an early age. In Israel, where children are commonly fed peanut  
proteins at an early age, the prevalence of peanut allergy appears to be much 
lower than in the western world (Du Toit et al. 2008). The number, type and 
variety of the enteric flora also seem to play a role in food allergy. In humans, 
specific differences in the composition of intestinal microbes have been noted 
between allergic and non- allergic children (Vickery et al. 2011). This area 
would benefit from further research. 
 
Relatively few food proteins account for the vast majority of food allergy 
(Radauer  & Breiteneder 2007; Sicherer & Sampson 2010), suggesting that 
major food  allergens may share specific properties which render them more 
allergenic than other food proteins. These properties include the fact that they 
are all water-soluble glycoproteins, relatively similar in size (10-70kd in size), 
and relatively stable  against denaturing by heat, acid or proteases (Sicherer & 
Sampson  2010).  Processing of food proteins also seems to play a role in their 
allergenicity. Heating or baking of egg and milk render them tolerable to  most  
egg-  or  milk-allergic  patients (Wang & Sampson 2009), whereas roasting 
peanuts increases their allergenicity, likely through a Maillard reaction (Wang 
& Sampson 2009). The carbohydrate moiety attached to an allergen may also 
play a role in the immune response to the allergen (Sicherer & Sampson 2010; 






Allergic disease is therefore the result of a complex interplay between host and 
environment. The various components of our immune system are highly 
evolved in their ability to encounter large quantities of foreign antigen on a 
daily basis, and differentiate pathological from harmless. Abnormalities in the 
way these antigens are detected, processed and responded to, result in the 
formation of allergy. Although an increasing variety of allergic conditions are 
known, many share common pathophysiological mechanisms.  Genetic  
predisposition,  in  hand  with  environment exposure and possibly our 
interaction with our microbiome, all play      a role in the formation of allergic 
disease. Although we know more about the aetiology of allergy than ever 
before, many questions still require answering before further impacts can be 
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BURDEN OF ALLERGIC DISEASE 
 
 
Allergic disease represents one of the most common set of illnesses worldwide, 
and has increasingly become a global health problem (Mallol et al. 2013; 
Pawankar et al. 2008). The combined impact of allergic disease on morbidity 
(Mallol et al. 2013; Ait-Khaled et al. 2007; Lai et al. 2009; Williams et al. 
1999) and mortality (Lozano et al. 2012) is profound, and increasing attention 
is being paid to the quality of life of people who suffer from allergic illnesses. 
As the burden of communicable diseases gradually decreases (Lozano et al. 
2012), the impact of non-communicable diseases comprises a larger proportion 
of overall mortality and morbidity, and deserves more attention in efforts to 
promote and improve health. 
 
Allergic disease affects people of all socioeconomic and ethnic backgrounds 
(Mallol et al. 2013), although there are still significant differences in 
prevalence and severity between countries (Partridge 2009). The prevalence of 
allergic disease is rising in many countries, whilst in others is is plateauing or 
even decreasing (Mallol et al. 2013; Asher et al. 2006). The reasons for these 
changes are not yet known, and are directions for further research. 
 
In contrast to the developed world, the significant burden of infectious diseases, 
combined with the relative scarcity of resources, has meant that asthma and 
allergic disease has traditionally not been a priority for governments, public 
health officials or researchers in the developing world (Zar et al. 2007). Much 
of the prevalence data for allergic illnesses comes from the developed world, 
although there have been many admirable recent efforts in South Africa to 
rectify this situation (Zar et al. 2007; Gray et al. 2014; Gray et al. 2015; Kung 
et al. 2014; Basera et al. 2015). 
 
Initially, data from South Africa suggested that the prevalence of asthma was 
much lower than in the developed world (Van Niekerk et al. 1979), and that 
there was a significant gradient in prevalence between urban and rural children. 
More recent data (Zar et al. 2007) has shown prevalence figures comparable 
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with  the  developed world, and there is some evidence that suggests that the 
urban-rural divide has narrowed (Steinman et al. 2003; Levin et al. 2011). 
The increase in prevalence of allergic disease, particularly in rural 
communities, is hypothesised to be related to the adoption of a more western 
lifestyle (Weinberg 2000). 
 
Unfortunately, diagnosis and management of allergic conditions still face many 
challenges in South Africa. Despite the excellent quality of local guidelines and 
protocols, uptake of these guidelines remains poor (Reddel et al. 2015). 
Asthma, in particular, remains a serious threat to public health, with data 
suggesting not only  that our prevalence is still increasing rapidly, but that our 
mortality rate is one of the highest in the world (Green et al. 2007). Research 
from the United States of America suggests that African Americans have not 
only a higher prevalence of asthma than their Caucasian counterparts, but 
unacceptable and disproportionately high rates of hospitalisation and mortality 
(Gupta et al. 2006). There is no recent South African literature that has looked 
at the influence of race, specifically, on allergy morbidity  or mortality. 
Rectifying the morbidity and mortality associated with allergic disease will 
require a concerted effort from government, public health officials, health 
practitioners and researchers. 
 
Asthma 
Asthma remains the best studied disease within the spectrum of allergy. With 
a global prevalence of 14.1% in 13-14 year old children (Mallol et al. 2013) 
and  11.4% in 6-7 year old children (Mallol et al. 2013), it is one of the most 
common severe childhood illnesses worldwide. In 2010, almost 350 000 people 
worldwide (Lozano et al. 2012) were believed to have died from asthma, with 
an age- standardised death rate of 5.2 per 100 000 (Lozano et al. 2012). Apart 
from mortality, asthma sufferers experience significant morbidity, including 
hospital admission, absence from school or work, and significant limitation of 
activity (Green et al. 2007). 
 
The prevalence of asthma amongst South African children is increasing (Zar et 
al. 2007), in contrast to the situation in some parts of the developed world, 
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where prevalence figures seem to be stabilising (Asher et al. 2006). Early South 
African data suggested that asthma was uncommon amongst Black African 
children. Van Niekerk et. al. (1979) found a prevalence of exercise-induced 
bronchospasm  of 3.17% and 0.14% for urban and rural Xhosa children 
respectively, in their study. At the time, the prevalence of asthma in the urban 
population was not significantly different from other data published in the 
developed world, and the authors postulated the low prevalence of asthma 
amongst rural Xhosa children to be due to environmental determinants rather 
than any genetic variation due to ethnicity. However a study in 2003 found a 
prevalence of bronchial hyper-responsiveness (based on histamine challenge) 
of 34.4% and 17% for similar populations (Steinman et al. 2003). Additional 
data has confirmed increasing rates of asthma amongst urban and rural Black 
African individuals (Mashalane et al. 2006; Calvert & Burney 2010; Levin et 
al. 2011; Steinman et al. 2003), and shows a narrowing of the urban-rural 
gradient (Steinman et  al. 2003; Calvert & Burney 2010; Levin et al. 2011). 
Unlike in the developed world, the relationship between atopy and asthma is 
not well established in South Africa, and the  developing world in general 
(Abbott et al. 2013). This merits further research, as it is possible that different 
pathophysiological mechanisms are at play in comparison  with those described 
in the literature originating from the developed world. 
 
The increased prevalence of asthma in South Africa is theorized to have 
occurred through increased urbanisation and adoption of a western lifestyle 
(Zar et al. 2007). It is not yet clear what aspects of urban life lead to an 
increased susceptibility to asthma, but possibilities include parental smoking, 
house dust mite exposure, decline in exposure to infectious diseases, 
differences in the pattern of gut microbial colonisation, exposure to domestic 
fuels, exposure to industrial pollution, dietary changes and overcrowding, 
amongst others (Weinberg 2000; Zar et al. 2007). Of concern is the relationship 
between socioeconomic status and asthma. Recent evidence (Poyser et al. 
2002) has shown that asthma prevalence is directly proportional to 
socioeconomic status in South Africa. Conversely, the prevalence of severe 
symptoms seems to have an inverse relationship with socioeconomic status 
(Poyser et al. 2002), implying that people with limited resources bear the brunt 
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of asthma morbidity. 
 
In addition to the problem of increasing asthma prevalence, children in the 
developing world in general, and South Africa in specific, seem to have more 
severe asthma (Poyser, Nelson, et al. 2002), as well as higher mortality (Beran 
et al. 2015). In the Global Burden of Asthma report, South Africa was ranked 
25th  in terms of asthma prevalence, but fourth in asthma case fatalities and fifth 
in case fatality rates (18.5 per 100 000 asthmatics) (Zar et al. 2007). Local data 
(Green et al. 2007) suggests that a high proportion of asthmatics suffer regular 
activity limitation and night symptoms, with more than half missing a day of 
school or work in the past 12 months, and 16% being admitted to hospital in 
the past year. Possible explanations for the high case fatality and frequency of 
severe symptoms include inadequate diagnosis, inadequate and inequitable 
access to care, poor patient understanding of the mechanisms and severity of 
their illness and poor socioeconomic conditions leading to an overall poorer 
quality of health (Beran et al. 2015; Poyser et al. 2002). Genetic predisposition 
to asthma severity on a racial basis has been suggested, but requires further 
research (Barnes et al. 2007). 
 
Many challenges will need to be met in order to improve these statistics. These 
include, but are not limited to, improved strategies for a coordinated approach 
to asthma as a public health problem, improved uptake of international and 
local guidelines in the diagnosis and management of asthma, better access to 
care, negotiation with pharmaceutical companies to provide cost-effective 
treatments to people who need them, and interrogation of some of the 
modifiable root causes of poor health (Bateman et al. 2008; Beran et al. 2015). 
These root causes include improvement of socioeconomic conditions and 




Allergic rhinitis is perhaps the most common chronic respiratory illness 
globally (Pawankar et al. 2008). The prevalence of allergic rhinitis has been 
estimated at 14.6% and 8.5% amongst 13-14 year old children and 6-7 year old 
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children respectively (Mallol et al. 2013), and it is estimated to occur in about 
500 million people (Ozdoganoglu & Songu 2012). Like many other allergic 
disorders, the prevalence of allergic rhinitis seems to be increasing (Asher et 
al. 2006), and there is wide variation in the prevalence data between countries, 
from 1% to 45% in 13-14 year old children in ISAAC (International Study of 
Asthma and Allergies in Childhood) (Aït-Khaled et al. 2009). Similarly to 
asthma, the prevalence of allergic rhinitis seems to be higher in higher income 
countries, but the prevalence of severe symptoms is higher in less affluent 
countries (Aït-Khaled et al. 2009). The reasons for the wide variation in 
prevalence are not yet known, and represent directions for further research. 
Although, in isolation, allergic rhinitis is not associated with mortality, 
sufferers experience significant morbidity and decreased quality of life 
(Ozdoganoglu & Songu 2012). People with allergic rhinitis frequently 
experience comorbidity with allergic conjunctivitis, asthma and eczema (Asher 
et al. 2012). 
 
Until recently, large-scale estimates of prevalence and morbidity in South 
Africa were lacking. Phase I and phase III of ISAAC have shown a very high 
prevalence (30.4% in 1995 and 38.5% in 2002) and suggest that the prevalence 
in increasing (Zar et al. 2007). Further analysis of the ISAAC phase I data from 
South Africa suggests an increase in allergic rhinitis with increasing 
socioeconomic status (Mercer et al. 2004), but noted potential confounding due 
to difficulty in standardization of self-reports of allergic rhinitis. In addition, 
pupils from low socioeconomic backgrounds who attended traditionally higher 
socioeconomic schooling showed increased susceptibility to some rhinitis 
symptoms (Mercer et al. 2004). It is likely that similar factors play a role in the 
increasing prevalence and socioeconomic discriminators that are seen with 
regards to allergic rhinitis, when compared with asthma statistics (Zar et al. 
2007). Further research is needed to better quantify the burden of disease, 
morbidity and cost of allergic rhinitis in a South African context. 
 
IgE-mediated Food Allergy 
The global prevalence of IgE-mediated food allergy ranges from 1-10% 
depending on the geographical area and patient age (Gray et al. 2014). 
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Gathering accurate prevalence data for food allergy has been difficult because 
many studies have relied on self- or parent-reported symptoms, and relatively 
few studies have used oral food challenge tests (which is considered to be the 
gold standard diagnostic test) (Prescott & Allen 2011). Even tests using oral 
food challenge as a diagnostic criterion have suffered from poor challenge 
participation rates (Prescott & Allen 2011). Prevalence of food allergy tends to 
lag behind other allergic diseases in the developed world (Kung et al. 2014), 
and evidence is emerging that suggests an increase in food allergies in these 
locations (Kung et al. 2014). This has led to the description of food allergy as 
“the second wave” of the allergy epidemic (Prescott & Allen 2011). There is 
good evidence from the developed world that food allergy causes significant 
morbidity,  and  severely  impacts  quality  of  life  for  patients  and  their     
families (Walkner et al. 2015). Of concern, children in the current generation 
seem to be less likely to outgrow food allergy than their predecessors (Prescott 
& Allen 2011). 
 
Food allergy was unfortunately not included in ISAAC, and there is very little 
local literature regarding prevalence and morbidity. Recently, the South 
African Food sensitisation and Food Allergy (SAFFA) study has published its 
interim results (Basera et al. 2015). The trial utilises robust methodology, using 
SPTs and a history of reaction to major food allergens to assess sensitisation, 
and correlating the prevalence of food sensitisation with proven food allergy 
by means of a rigorous open incremental oral food challenge. In their interim 
results, they report a prevalence of sensitization to any food allergen of 9.6% 
(wheal size ≥ 3mm larger than control), and a prevalence of challenge-proven 
IgE-mediated food allergy of 2.5% (Basera et al. 2015). The authors note that 
the prevalence of sensitization to at least one food is higher than previously 
reported in Africa, but that the prevalence of challenge-proven IgE-mediated 
food allergy remains on the lower end of the international spectrum (Basera et 
al. 2015). Whilst the final results of the SAFFA study are yet to be published, 
it is expected to provide interesting and important insights into the burden of 
food allergy in South Africa. Local literature with regards to food-induced 
anaphylaxis is restricted to case reports, and accurate statistics regarding 





According to ISAAC, the global prevalence of atopic eczema is 7.3% and 7.9% 
for 13-14 year old children and 6-7 year old children respectively (Mallol et al. 
2013). There is, once again, a wide variation in prevalence between countries 
(from <1% in Albania to over 17% in Nigeria in the 13-14 year old age group) 
(Williams et al. 1999), and even within countries (Mallol et al. 2013). Atopic 
eczema has been shown to have significant physical, psychosocial and 
emotional effects on children (Carroll et al. 2005), as well as significant 
emotional and financial effects on families (Carroll et al. 2005). Patients with 
atopic eczema frequently report lower quality of life than controls or people 
with other chronic skin conditions (Carroll et al. 2005; Lewis-Jones 2005). 
 
ISAAC has, again, provided the most robust data regarding the prevalence of 
atopic eczema in South Africa. The trend towards increasing prevalence was 
consistent  with those of asthma and allergic rhinitis (Zar et al. 2007). ISAAC 
showed an increase in prevalence from 11.8% to 19.4% from phase I to phase 
III (Zar et al. 2007), and the study also gave some estimate of impact on quality 
of life, showing  an increase in the prevalence of sleep disturbance from 8.4% 
to 15.7%. Again, further research into the burden of disease of atopic eczema 
in South Africa is urgently awaited. 
 
In summation, allergic disease is a global health problem of increasing 
proportions. Allergic conditions contribute significantly to global morbidity 
and mortality, and have significant effects on the quality of life of sufferers and 
their families. Recent large-scale international trials and collaborations have 
provided new insights into the magnitude of the burden of allergic disease on 
society, and provide insight into directions for further research. 
 
The burden of allergic disease in South Africa has not received enough 
attention, despite significant recent efforts. The prevalence of most common 
allergic diseases seems to be increasing over the past thirty years, and our 
morbidity and mortality statistics are alarmingly high. Poverty and inequality 
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in both socioeconomic conditions and access to quality care likely contribute 
to the high morbidity and mortality rates of asthma, and it is reasonable to 
suggest that they impact morbidity and quality of life for patients suffering 
from other allergic conditions. There is an urgent need for further research, as 
well as for a coordinated approach towards  caring for South Africans affected 
by allergic disease. 
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GENETICS AND ALLERGY 
 
 
Although the evidence of a genetic basis for asthma and allergic disease is well 
established (Los et al. 2001; Barnes 2010a; Dávila et al. 2009; Hong et al. 
2009), much work remains to be done in both discovering which genes are 
involved and evaluating the nature of the relationship between genotype and 
phenotype (Vercelli 2008). As previously stated, improved understanding of 
disease phenotypes and endotypes will hopefully yield improved results in 
genotype-phenotype correlation research. Modern genetics has, over the past 
thirty years, allowed the complete location and characterisation of many 
monogenic illnesses (Lander & Schork 1994), however the reality is that most 
human illnesses occur as a result of a complex interplay between multiple 
genes as well as environmental factors (Lander & Schork 1994). In the study 
of polygenic illnesses, a thorough understanding of the nature of genetic 
inheritance, and the potential interactions between alleles, the genes  on which 
they are found, and the environment, is essential to ensure that research is 
accurate and reproducible (Lander & Kruglyak 1995). Novel techniques, 
including genome-wide association studies (GWAS), work hand-in-hand with 
more robust methods of statistical analysis, as well as advances in 
immunopathology. These methods have allowed us not only an improved 
understanding of the genetics of complex illnesses, but also to better define 
clinical and laboratory phenotypes, allowing for more accurate 
characterization of patients and their illnesses, and guiding further research 
(Meyers 2010). Nonetheless, much work remains to be done in this rapidly 
evolving field. 
 
Genetics and Inheritance 
The most common form of genetic variation in the human genome is the single- 
nucleotide polymorphism (SNP) (International HapMap Consortium 2003), 
which refers to the variation, between individuals, of single alleles at any given 
locus. It is estimated that about 11 million SNPs with a frequency of both 
alleles of ≥ 1% occur in the human genome (Kruglyak & Nickerson 2001), 
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accounting for >90% of the genetic variation in the population (International 
HapMap Consortium 2003). As the mutation rate is very low relative to the 
number of generations since the most recent common ancestor of any two 
people, nearly every SNP site results from a single mutation event 
(International HapMap Consortium 2003). A few (generally uncommon) 
illnesses result from single mutations, and are referred to as monogenic 
(Rosenwasser & Borish 1997). This group of illnesses includes cystic fibrosis, 
Huntington’s Chorea and Tuberous Sclerosis, amongst others. More 
commonly, disease results from variations in multiple genes, and the complex 
interactions that result between these genes and the environment (Rosenwasser 
& Borish 1997). 
 
Meiosis, Haplotypes and Linkage Disequilibrium 
During meiosis, pairs of homologous chromatids (derived, respectively, from 
paternal and maternal chromosomes) exchange genetic material in a process 
known as meiotic recombination (Collins 2009). This process results in the 
gamete (sperm or oocyte) receiving a recombined chromosome consisting of 
maternally and paternally derived genetic material (Collins 2009). By using 
certain informative polymorphisms as markers, it is possible to derive the 
location of meiotic chromosome breaks (Collins 2009). It is then possible to 
estimate the relative distance from the marker SNP to a potential disease-
associated SNP by assessing the degree of recombination between the two 
SNPs (International HapMap Consortium 2003). The closer together the two 
polymorphisms, the less likely they are to recombine freely (International 
HapMap Consortium 2003). 
 
A specific set of alleles observed on a single chromosome (or part of a 
chromosome) is called a haplotype (International HapMap Consortium 2003). 
New haplotypes can be formed by mutations, or by recombination of maternal 
and paternal genetic material during meiosis (International HapMap 
Consortium 2003). This recombination seems to occur more frequently in 
certain regions of any given chromosome than in other regions, leading to the 




Linkage disequilibrium refers to the coinheritance of alleles at different loci, 
leading to associations between these alleles in the population (International 
HapMap Consortium 2003). Although the strength of association (or degree of 
linkage disequilibrium) between the two alleles depends on several factors, the 
strongest determinant of this association is the physical distance between them 
(Collins 2009). Association studies between marker and disease SNPs can 
therefore be used as a powerful tool in mapping the physical location of 
potential disease-causing alleles (Collins 2009). 
 
Conversely, a study which aims to investigate a relationship between a SNP 
believed to play a role in the formation of a specific illness may be affected by 
confounding if linkage is not adequately investigated (Aissani 2014). 
Fortunately, the impact of confounding by linkage disequilibrium on 
association studies of common conditions may be small if the gene under 
investigation has only a small to moderate effect on the disease in question 
(Aissani 2014), as is the case for many common polygenic diseases. 
 
Hardy-Weinberg Equilibrium 
Hardy-Weinberg equilibrium can be defined as “…the state of the genotypic 
frequency of two alleles of one autosomal gene locus after one discrete 
generation of random mating in an indefinitely large population.” (Mayo 
2008). If the two alleles are  A and a, with frequencies p and q (=1-p), then the 
frequencies for the  genotypes AA, Aa, and aa are p2, 2pq and q2  respectively 
(Mayo 2008). The central tenet of Hardy-Weinberg equilibrium is that a 
population that is sufficiently large, and continues to mate at random, will 
maintain these allelic and genotypic frequencies in the absence of external 
forces, including natural and artificial selection, mutation, non-random mating, 
migration and inbreeding (Mayo 2008). In reference to association testing, 
evaluating SNPs for Hardy-Weinberg equilibrium assists us in determining 
that our sample population is in equilibrium for that specific SNP, and helps 
us to identify problems in sampling stratification or in genotyping (Wigginton 
et al. 2005). Testing SNPs for Hardy-Weinberg equilibrium is important, as 
deviations may indicate significant problems in the data set (Salanti et al. 
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2005). In contrast, in other genetic association studies, deviation from Hardy-
Weinberg equilibrium may allow inferences that the SNP in question is 
associated with the disease under investigation (Salanti et al. 2005). 
 
Methods of associating genes with disease 
Much of our initial understanding of the genetic inheritance of asthma and 
allergic disease came from large family and twin studies (Los et al. 2001). The 
complexity of inheritance of asthma and allergy can be attributed in part to 
many factors, including: that their pathogenesis is determined by many 
different genes (polygenic), different sets of genes interact in different families 
and racial groups (genetic heterogeneity) and that the same gene or set of genes 
can cause multiple different traits (pleiotropy) (Los et al. 2001). 
 
There has been a rapid increase in the amount of information on 
polymorphisms in human genes (Daly & Day 2001). The human genome is 
highly polymorphic, with polymorphisms occurring on average once every 
fifty to one hundred base pairs (Daly & Day 2001). Some polymorphisms have 
a significant functional effect on the gene product, whilst others are useful as 
markers (Daly & Day 2001). 
 
Multiple approaches have been used in the investigation of the inheritance of 
allergic diseases, and a few bear specific mentioning. Candidate gene analysis 
involves identifying genes which have a plausible physiological basis for 
conferring susceptibility to the disease in question (Vercelli 2008). Allele or 
genotype frequencies can then be compared between unrelated cases and 
controls (Vercelli 2008). Linkage analysis focuses on families that contain 
individuals who have the disease in question. The analysis involves genotyping 
family members with evenly spaced genetic markers, looking for areas that 
show a higher than expected amount  of shared alleles among affected 
individuals (Vercelli 2008). This can be followed  by positional cloning to 
narrow down the area of interest to a specific polymorphism (Vercelli 2008; 




In the past ten to fifteen years, the ability to identify and map an enormous 
number  of SNPs and the concurrent advances in genotyping technology has 
led to the adoption of GWAS as the method of choice for investigating genetic 
disorders with complex inheritance models (Lockett & Holloway 2013). This 
powerful tool involves the simultaneous examination of hundreds of thousands 
of known SNPs in unrelated cases and controls (Willis-Owen et al. 2009), and 
is an excellent test for polymorphisms  that  confer  small  or  moderate  risk  
toward  the  disease under investigation (Vercelli 2008; Zhang et al. 2012; 
Lockett & Holloway 2013). Advantages of GWAS include that they can assess 
the entire genome, and that they have the ability to detect polymorphisms with 
relatively small effect size (Willis-Owen et al. 2009). Using GWAS, 
researchers have been able to both confirm associations between previously 
implicated genes and allergic disease, and uncover previously undiscovered 
regions of interest (Zhang et al. 2012). An excellent example of this is the 
association of the transmembrane protein ORMDL3 with childhood asthma 
(Moffatt et al. 2007) in an early GWAS. 
 
Gene-environment interactions 
The rapid increase in the global prevalence of asthma and allergic disease in 
the past two to three decades is considered to have occurred too quickly to be 
explained by changes in the genome sequence alone (Tan et al. 2012; Lee et 
al. 2015). It is hypothesised, but not yet proven, that this increase is occurring 
mostly in people at genetic risk of allergic disease (Tan et al. 2012). The most 
likely causes of this rapid increase are environmental factors (Blumenthal 
2012). There is increasing evidence that the interaction between genetic and 
environmental factors may play an  important role in the pathogenesis of 
aetiologically complex disease such as asthma (Vercelli 2004). The 
relationship between these interactions and the pathogenesis of allergic disease 
is complex, and non-linear (Vercelli 2004), meaning that the same genotype 
may be associated with the opposite phenotype in different environments 
(Vercelli 2004). 
 
Environmental exposures have been linked epidemiologically with the 
development of asthma and allergic disease (Martino 2011). Furthermore, 
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microbial burden, environmental pollution and dietary changes have all been 
shown to affect gene expression and immune function (Martino 2011). The 
study of epigenetics provides us with a mechanism by which to explain the 
impact of these exposures on gene expression. Variation in gene expression is 
the primary reason that cells of multicellular organisms differ significantly in 
structure and function, whilst being genetically identical (Vercelli 2004). Many 
of these differences occur during development, especially in-utero (Prescott & 
Saffery 2011), and are retained during mitosis (Vercelli 2004). Although they 
do not involve mutations of the DNA itself, and are therefore reversible, they 
are heritable in the short term (Vercelli 2004). 
 
These changes are referred to as epigenetic, and include histone methylation 
and acetylation, as well as DNA methylation, amongst others (Martino 2011). 
Epigenetic activation of a silent gene, or conversely silencing an active gene, 
may cause differing phenotypic effects in individuals with an identical 
genotype (Blumenthal 2012). 
 
Several studies have looked at epigenetic effects on immune regulation in 
allergic disease (Prescott & Saffery 2011). Of particular interest is the 
influence of epigenetic modification on the differentiation of naïve T-helper 
cells (TH0) into either TH1 or TH2 cells (Harb & Renz 2015). Although 
evidence for the effect of epigenetic modification on the development of 
allergic disease is accumulating, much still  needs to be understood about their 
exact mechanisms (Harb & Renz 2015). 
 
Gene-gene interactions 
Although the fact that genetic interaction plays a role in determining phenotype 
is beyond question (Steen 2012), quantifying the effect in specific disease 
states has proven to be highly complex. One of the major obstacles has been in 
the very definitions of ‘gene-gene interaction’ and ‘epistasis’, two often 
interchangeably-used terms in genetics (Wang et al. 2010). In addition, there 
is little agreement in the literature with regards to how to delineate genuine 
gene-gene interaction, which in itself is relatively uncommon, from 
interactions between gene products (Wang et al. 2010). The more complex a 
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specie’s genome, the greater the number of gene-gene interactions. This means 
that possibly the major limitation of comprehensive analyses of genetic 
interactions is the sheer number of these potential interactions (Phillips 2008). 
The effects of a polymorphism at a specific locus may be obscured by 
interactions with other loci (Phillips 2008), making mapping very difficult. 
 
Despite these obstacles, advances in genetics, high throughput functional 
genomics, statistical regression analysis as well as systems biology have made 
it possible for  the first time for us to examine gene-gene interactions in a 
unified and functional manner (Phillips 2008; Cordell 2009). Several studies 
have looked at associations between different SNPs and asthma or allergic 
disease, with interesting results (Godava et al. 2013; Wang et al. 2013; Choi et 
al. 2012), however more work needs to be done to elucidate the exact nature 
of gene-gene interactions in allergic disease. 
 
South African Literature on Genetics and Allergy 
The burden of infectious disease, as well as the previously prohibitive cost of 
genotyping, has precluded thorough study of the association between genetic 
polymorphisms and allergic disease in South Africa. The local literature is 
restricted to very few studies, with most reporting very small sample sizes. One 
example involved the description and characterisation of a new SNP in a child 
with asthma, which was also found to exist in his mother. The subject SNP is 
on chromosome 14q in the gene coding for α1-antitrypsin (Pillay et al. 2001; 
Mahadeva et al. 2001). Another small study investigated the association 
between two polymorphisms in the β-2 adrenoceptor and atopy (Potter et al. 
1993). The study found no significant association, but was too limited in 
sample size to draw any firm conclusions. 
 
A slightly larger study investigated the relationship between three 
polymorphisms in the beta chain of the high-affinity immunoglobulin E 
receptor (Fcε-RIβ) and asthma, with some interesting results (Green et al. 
1998). An SNP at position 181, I181L,  was significantly associated with 
asthma in White patients, whilst a different SNP (E237G) was significantly 
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associated with asthma amongst Black African patients.  In other studies, this 
polymorphism was associated with bronchial hyper- responsiveness, even in 
the absence of atopy (Green et al. 1998). The authors suggested this 
polymorphism as a possible explanation for the increased severity of asthma 
and increased mortality amongst Black African people with asthma. However, 
their sample size was again a limiting factor. 
 
Variations in Genetics and Allergy Based on Ethnicity 
There is strong evidence in the international literature that suggests that 
asthmatics  of Black African origin suffer much higher morbidity and mortality 
than their Caucasian counterparts (Barnes 2010c; Joseph et al. 2006; Leong et 
al. 2012). Although asthma and allergy symptom severity has also been shown 
to be related to socioeconomic status (Lai et al. 2009; Williams et al. 1999), 
there is increasing data to show that at least part of this variation may be due 
to genetic variation between ethnic groups (Barnes 2010c). It is not yet known 
how much of the variation in phenotype is due to genetic discrepancies at the 
level of ethnicity, and difficulties in unbundling  ethnicity  (or  ancestry)  from  
the  social  and  economic  constructs that accompany racial classification make 
accurate comparisons even more difficult (Leong et al. 2012). 
 
Most of the GWAS data with regards to asthma and allergic disease comes 
from cohorts of people of European ancestry (Barnes 2010c). The limited 
GWAS data on people of African or Hispanic origin suggests that different 
genes may be at play in people of non-European ancestry (Mathias et al. 2010; 
Barnes 2010c), or even that the same polymorphisms may cause different or 
opposite effects in people of different ethnicities (Barnes 2010c). On one hand, 
genetic admixture makes studying the effect of a specific ethnicity on allergy 
risk more difficult and, on the other, helps us to assess the relative contributions 
of different ethnicities to allergy risk in a specific individual or population 
(Barnes 2010b). Although most of this data is related to asthma, similar results 
have been seen in studies of the filaggrin gene and atopic eczema (Thawer-
Esmail et al. 2014). In addition to differences in severity of symptoms, there is 
some evidence that genetic variation in ethnicity may have therapeutic 
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implications. In specific, variations in the frequency of SNPs in the ®-2 
adrenoceptor may imply a poorer response to β-agonist therapy in people of 
African or Chinese origin (Xie et al. 1999). 
 
Recent studies from the Americas (Vergara et al. 2013; Flores et al. 2012) 
confirm African ancestry as an independent risk factor for asthma and raised 
serum IgE levels, and affirm the need for further research in order to qualify 
this and similar relationships more fully. 
 
Evidence for Evolutionary Adaptation in Immune Responses 
Insufficient research has been performed to quantify the genetic factors that 
predispose to asthma and allergy in populations other than Caucasians (Barnes 
2010c). This notwithstanding, many studies have noted that populations of 
differing ethnicities have different allele frequencies for many different genes 
(Le Souëf et al. 2006). Some authors (Le Souëf et al. 2006; Le Souëf et al. 
2000) propose evolutionary adaptation in human immune responses as a 
plausible mechanism for this phenomenon, and it is against this background 
that our study is being performed. The hypothesis put forward is that 
populations originating in tropical environments, where they would have 
frequently encountered helminths and other parasites (Le Souëf et al. 2000), 
develop an immune system predisposed to mounting a strong TH2 response. 
This could conceivably confer a survival advantage in such climates (Le Souëf 
et al. 2006). Upon migration to colder climates, where parasites and helminths 
would be much less prevalent (as they rely on heat and humidity to thrive  
(Stromberg 1997)), the balance between the benefit of this inflammatory 
immune profile and the risk of having a strong immune response against 
‘harmless’ environmental proteins, shifts significantly (Le Souëf et al. 2000). 
 
This has led to the prediction that people of tropical origin will show a higher 
prevalence of pro-inflammatory alleles (Le Souëf et al. 2000), and will 
subsequently have an increased predisposition to inappropriate immune 
responses (including allergy) if rapidly relocated to temperate areas (Le Souëf 





In conclusion, the genetic basis for allergic disease is undisputed, but the nature 
of the complex association between multiple genes, as well as environmental 
influences, remains to be fully explained. As complex illnesses, allergic 
diseases are likely caused by the relatively small effects of multiple genes. 
When acting in concert, and in the presence of specific environmental cues, the 
effect on phenotype can be profound. 
 
Until recently, our ability to examine the genetic causes of allergic disease was 
hampered by an incomplete understanding of the immunopathology of allergic 
phenotypes, the inability to sequence large sections of the genome in parallel, 
and  the lack of statistical tools to examine complex interactions with sufficient 
power  and accuracy. Advances in multiple areas of research including 
genetics, immunology and statistics have enabled us, for the first time, to begin 
to unravel the nature of the pathway from genotype to phenotype, and the 
complex interactions that underpin this pathway. 
 
As our ability to examine the genetics of asthma and allergy has increased, the 
discovery of interactions between genes and the environment, as well as 
between different genes, has made analysis more complicated. Epigenetic 
modification of DNA is an understudied but important phenomenon that will 
help to enhance our understanding of why people with the same genotype may 
have different allergic phenotypes. Novel techniques are also helping us to 
begin to understand how gene- gene interactions help relatively minor 
alterations in the genome to have profound phenotypic effects. 
 
The study of the relationship between genetics and allergic diseases in South 
Africa, and particularly amongst Black African and mixed race people, 
remains in its infancy. Hopefully the falling costs of high-throughput 
genomics, and an increasing interest in novel polymorphisms will help to 
rectify this situation. The possible influence of evolution on the genetics of 
asthma and atopy is a relatively novel hypothesis. This study forms a small 
part of efforts to investigate this further, and of on going efforts to better 
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understand the genetic aetiology of asthma and allergies amongst people of 
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CD14 is a molecule expressed on and secreted by myeloid cells (Vercelli 
2002). Membrane-bound and soluble CD14 bind a variety of bacterial products 
including lipopolysaccharide (LPS) from gram-negative bacteria and 
lipoteichoic acids from gram-positive bacteria (Vercelli 2002). At a molecular 
level, CD14 acts by transferring LPS and other ligands to the Toll-like 
receptor/MD-2 signalling complex. Activation of this complex results in the 
initiation of innate host defence mechanisms, including release of 
inflammatory cytokines that are key to promoting  a TH1 response (Vercelli 
2002). 
 
A C-T polymorphism at position 159 in the promoter of CD 14 (159T>C) has 
been postulated to modulate the cellular response to endotoxin (Sackesen et al. 
2011). Several studies in different populations have sought to correlate 
polymorphisms at this position with in-vitro (Sackesen et al. 2011; Baldini et 
al. 1999; Leung et al. 2003) and in-vivo (Koppelman et al. 2001; Kedda et al. 
2005; Lange et al. 2005) responses, many with conflicting results. Even recent 
meta-analyses (Zhao & Bracken 2011; Zhang et al. 2011; Xu & Wang 2014) 
have reached differing conclusions about the link between the polymorphism 
and allergic disease including asthma and allergic rhinitis. Another promoter 
polymorphism (550C>T) has been investigated in recent studies. The CC 
genotype has been found to correlate with allergic rhinitis (Zhang et al. 2011), 
and also with decreased IL-8 levels in workers exposed to dust that contained 
endotoxin (Rylander & Michel 2005). Although no prior studies have 
evaluated the prevalence or phenotypic effect of these polymorphisms in Black 
African populations, in a review of the international literature regarding the 
159T>C polymorphism, Zhang et al. (2008) looked at the allele frequencies as 
well as phenotypic associations in various populations around the world. They 
found a discrepancy in allele frequencies between different population groups, 
with people of African descent having the highest prevalence of the C allele, 
followed by Caucasians and then Asians (Zhang et al. 2008). Their review 
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underlines the significant discrepancy between studies in terms of  associations 
between either allele and phenotypic features of allergy, which they suggest 
may be due to methodological concerns, gene-gene or gene-environment 
interactions, amongst others (Zhang et al. 2008). 
 
ADRB2 
The β-2 adrenoceptor is widely distributed in human lung tissue, existing 
primarily  in airway smooth muscle, but also on other cells including epithelial 
and endothelial cells, type II cells and mast cells(Johnson 1998). The principal 
effect of β-2 adrenoceptor activation is smooth muscle relaxation and 
alleviation of bronchoconstriction (Bertics et al. 2003). The β-2 adrenoceptor 
gene is situated on the long arm of chromosome 5, and codes for an intronless 
gene of approximately 1200 base pairs (Johnson 2006). The gene is highly 
polymorphic, containing eighteen SNPs, of which four code for amino acid 
substitution (Hall & Sayers 2007). Three polymorphisms have been described 
in detail: 46G>A(Arg16Gly), 79G>C(Gln27Glu) and 491C>T(Thr64Ile) (Hall 
1996). 
 
Clinical interest in the β-2 adrenoceptor gene is two-fold. Firstly, there has 
been much speculation as to whether polymorphisms in this gene alter 
susceptibility to or severity of asthma. Initially, an inverse relationship 
between FEV1 and β-2 adrenoceptor density has been reported (Johnson 1998). 
However, it is still unclear (despite several studies) exactly what the 
phenotypic effects of these polymorphisms are (Holloway & Yang 2005). A 
meta-analysis in 2005 found that neither the Arg16Gly nor Gln27Glu 
polymorphisms were associated with overall asthma susceptibility or bronchial 
hyper-responsiveness, but that the Gly16 allele predisposes to nocturnal 
asthma, and may be associated with asthma severity (Contopoulos-Ioannidis 
et al. 2005). 
 
Secondly, there is a growing body of evidence to suggest that polymorphisms 
in the β-2 adrenoceptor gene have important effects in modulating responses 
to β-agonist therapy for asthma (Johnson 2006), particularly that 
polymorphisms may affect receptor downregulation in the face of long-term 
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usage. Initial studies focussed on short-acting β2 agonists, and a large-scale 
randomised cross-over study showed that individuals homozygous for the 
Arg16 allele failed to maintain responses to salbutamol (Israel et al. 2004).
Similar large-scale trials were, until recently, lacking for  longer-acting  agents,  
with one study suggesting a protective effect against receptor downregulation 
when a long-acting agent is combined with an inhaled corticosteroid (Bleecker 
et al. 2006). A recent multi-centre, double-blind, randomised placebo-
controlled trial in the USA showed improvement over placebo  in peak 
expiratory flow (PEF) in subjects receiving salmeterol, irrespective of 
Arg16Gly genotype (Wechsler et al. 2009). There was, however, evidence that 
Arg/Arg subjects had a significantly higher response (when compared to 
placebo) to metacholine challenge relative to Gly/Gly subjects. Another 
question that remains to be answered is whether individuals homozygous for 
the Arg16 allele should be given an alternative bronchodilator (Hall & Sayers 
2007). 
There have been no prior studies on the prevalence or phenotypic effects of β-
2 adrenoceptor polymorphisms in local populations, and very little published 
literature worldwide on people of African origin. Almost all the data on people 
of African origin comes from studies of African-American populations, and it 
is not yet clear how generalizable that data is to local populations, as they 
represent a genetically admixed population (Barnes 2010b). 
CMA1 
Mast cells and their various inflammatory mediators have been implicated in  
a variety of pathologic features of allergic disease (Hossny et al. 2008; Iwanaga 
et al. 2004). Multiple mediators are released from mast cells following 
activation, and among the most abundant is the protease chymase (Iwanaga et 
al. 2004). Chymase is a 226 amino-acid residue protein that is encoded by a 
single gene. The enzyme is stored in, and released in fully active form from, 
mast cell secretory granules (Iwanaga et al. 2004). Although the function of 
mast cells in allergic inflammation has been extensively described, the role of 
chymase is not yet fully understood, with research indicating both pro- and 
anti-inflammatory properties (Sharma et al. 2005). Evidence suggests that 
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chymase contributes to fibrosis and tissue remodelling by activating 
procollagenase, releasing transforming growth factor ®1(TGF-®1), and 
converting angiotensin I to angiotensin II (which it does more efficiently than 
angiotensin converting enzyme) (Weidinger et al. 2005). Several studies have 
explored the association between genetic polymorphisms in the CMA1 gene 
and atopic disease. To date, the evidence has been conflicting, and of 
insufficient quality to draw any firm conclusions. Two polymorphisms, an 
SNP in the promoter region of the gene, and a short tandem repeat (STR) 
downstream of the gene, have been reviewed. Results regarding associations 
between the SNP and asthma have been inconsistent (Hossny et al. 2008; 
Iwanaga et al. 2004). Investigation of a large cohort of adults in Switzerland 
revealed an association between a (TG)n(GA)m repeat and atopic asthma 
(Hersberger et al. 2010), which  was confirmed in smaller studies (Sharma et 
al. 2005; Hossny et al. 2008). 
 
IL-12 
IL-12 has been shown to be an important cytokine in the development of a TH1 
immune response (Hossny et al. 2008). In the presence of IL-12, naïve T-cells 
differentiate into TH1 cells, with production of TH1 cytokines (IL-2, IFN-γ) 
(Iwanaga et al. 2004) and generation of TH1 memory cells. IL-12 therefore 
plays an important role in antagonism of TH2 differentiation, and in initiating 
host defence against viral particles (Weidinger et al. 2005). IL-12 is comprised 
of 2 polypeptide chains that are bound by disulphide bonds. The first, a 35-kd 
chain, is encoded by IL12A on chromosome 3p12-q13.2. The second, a 40-kd 
chain, is encoded by IL12B on chromosome 5q31-33 (Martinez & Holt 1999). 
The IL12A gene has not been noted  to have any associations with asthma, 
allergic rhinitis or atopic dermatitis (Martinez & Holt 1999), however there are 
several studies which have looked at associations between polymorphisms in 
the IL12B gene and asthma in particular. 
 
Morahan and colleagues (2002) found no association between a promoter 
polymorphism of IL12B and asthma, but their data did suggest a significant 
association with asthma severity. Heterozygotes were found to be 4.6 times 
more likely to develop severe asthma. Interestingly, the polymorphism was 
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associated  with both atopic and non-atopic asthma, leading the authors to 
suggest IL12B polymorphisms as a “final common pathway” for progression 
to severe disease for both forms of asthma. Other studies (Khoo et al. 2004; 
Randolph et al. 2004) have failed to replicate this data. 
 
IL-13 
IL-13 is a TH2 cytokine which is a critical mediator of the inflammatory 
process of atopy and asthma (Corren 2013). It shares many functions with IL-
4 (Heinzmann et al. 2000), and has several unique functions in addition. 
Prominent functions of IL-13 include goblet cell differentiation, IgE class 
switching, fibroblast activation and facilitation of allergen-mediated bronchial 
hyper-responsiveness (Heinzmann et al. 2000; Corren 2013). The IL-13 gene 
is located on chromosome 5q31, a locus which has been linked to high serum 
IgE levels (Xu et al. 2000). 
 
The IL-13 receptor is a heterodimer comprising of IL-4Rα and IL-13Rα1 
(Chen et al. 2004). This receptor also acts as an alternate receptor for IL-4, 
which may partly explain the homologous effects of these two molecules 
(Chen et al. 2004). Many studies have looked at the effect of IL-13 
polymorphisms on asthma and atopy,  either in isolation or in conjunction with 
IL-4 and IL-4R polymorphisms. Two recent meta-analyses showed an 
association between the IL-13 1112C>T polymorphism and paediatric (Liu et 
al. 2014), and adult (Wang et al. 2013) asthma respectively. Another meta-
analysis (Ying et al. 2012) with a large number of cases and controls was 
unable to demonstrate an association between the same polymorphism and 
allergic rhinitis risk. The same authors did, however, find an association 




IFN-γ and IFN-γR1 
Although much focus is given to the contribution of TH2 cytokines to the 
development of allergy, an absence or decrease of certain TH1 cytokines may 
also play a significant role (Teixeira et al. 2005). IFN-γ is a pleiotropic 
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cytokine with diverse functions including response to viral, bacterial, 
mycobacterial and fungal pathogens, modulation of the immune response and 
even tumour surveillance (Schroder et al. 2004; Young & Hardy 1995; Billiau 
& Matthys 2009). It is produced by multiple immune cells in response to 
predominantly IL-12 secretion but also microbial stimuli (Smith & Denning 
2014). Initially called Macrophage Activating Factor (MAF), IFN-γ is an 
important cytokine in the innate and adaptive immune systems. Secretion by 
antigen presenting cells (APCs), such as those of the monocyte/macrophage 
lineage as well as dendritic cells, likely causes local effects including self-
activation and activation of local cells (Schroder et al. 2004). Early secretion 
by natural killer (NK) cells and possibly APCs is probably of great importance 
in initial host defence against infection, whereas TH2 lymphocytes are  the most 
significant secretor of IFN-γ in the adaptive immune system(Schroder et al. 
2004). The IFN-γ receptor (IFNGR) is made up of pairs of ligand-binding 
chains (IFNGR1) and signal-transduction chains (IFNGR2) (Schroder et al. 
2004). Signal transduction is effected predominantly via the Jak-Stat pathway 
(Subramaniam et al. 2001). 
 
Several authors have explored links between polymorphisms in the IFN-γ gene 
(located on chromosome 12) or the receptor genes (located on chromosome 6 
and 21 respectively (Dorman & Holland 2000)) and allergic disease. A recent 
meta-analysis showed an association between the AA genotype, at position 874 
(874T>A) in the IFN-γ gene, and asthma risk (Nie et al. 2014). This association 
was present in both Caucasian and Asian subjects. 
 
The evidence for polymorphisms in the IFNGR complex and allergic disease 
is somewhat more circumstantial. Pathogenic mutations in the IFNGR 
complex have been associated with, amongst others, mycobacterial infections, 
and susceptibility to viral infections (Dorman et al. 1999). However, there is 
limited evidence to suggest an association even between these pathogenic 
mutations and allergic disease (Wood et al. 2005). Non-pathogenic mutations 
have been shown to have a modest effect on serum IgE levels in certain 
populations (Gao et al. 1999), whilst other authors have suggested an 
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association between the IFN-γR1 mutation IFNGR -56T>C and ocular atopic 
dermatitis (Matsuda et al. 2007). These associations require further 
interrogation to determine their reproducibility. 
 
TGF-β 
TGF-β  was first named for its ability to induce tumour-like growth 
characteristics in normal cells (Salib & Howarth 2009), but it has subsequently 
been shown to have a wide array of functions, and to be secreted by a variety 
of cells (Bossé & Rola- Pleszczynski 2007; Makinde et al. 2007). It forms part 
of a superfamily  of  cytokines,  and  occurs  in  3  isoforms,  of  which  TGF-
β1  is  the  most extensively studied (Bossé & Rola-Pleszczynski 2007). TGF- 
β1 is synthesized as a 390 amino acid prepropeptide (Bossé & Rola-
Pleszczynski 2007). Although ubiquitously expressed, the level of expression 
is subject to extensive transcriptional and post- transcriptional regulation 
(Bossé & Rola-Pleszczynski 2007; Makinde et al. 2007).  In addition, the 
maturation, expression and activation of the protein are also extensively 
regulated (Bossé & Rola-Pleszczynski 2007). 
 
TGF-β is predominantly secreted by eosinophils, but is also secreted by many 
other cells, including macrophages, lymphocytes, fibroblasts, epithelial cells 
and  mast cells (Makinde et al. 2007). It is secreted in an inactive form, and a 
latency associated peptide must be removed to release the active form 
(Makinde et al. 2007). Several cytokines, including IL-5, IL-13 and TGF- 
β itself can induce its production and release, whilst IFN-γ plays an inhibitory 
role (Makinde et al. 2007). TGF-β mediates its effects via three receptors, 
namely TGF-βR1, 2 and 3, causing phosphorylation of intracellular 
serine/threonine kinase domains (Makinde et al. 2007; Bossé & Rola-
Pleszczynski 2007). The main pathway by which its effects are mediated is the 
Smad pathway (Bossé & Rola-Pleszczynski 2007), however other pathways 






TGF-β has many effects, of which several are relevant in allergic 
inflammation,  most notably in the asthmatic airway and in the nasal mucosa 
in allergic rhinitis. It is a potent chemoattractant of leucocytes, especially mast 
cells (Salib &  Howarth 2009). It also plays an immunoregulatory role, and is 
thought to impact the interaction between regulatory T cells (Tregs) and 
CD4+  cells (Salib & Howarth 2009). TGF-β also plays a role in wound 
healing. At low levels of activation, it induces the deposition of extracellular 
matrix to facilitate wound healing, however with sustained activation, 
excessive matrix deposition can lead to scarring and fibrosis (Salib & Howarth 
2009). 
 
There is considerable controversy over the role of TGF-β1 in allergic rhinitis 
(Salib & Howarth 2009) and asthma (Bossé & Rola-Pleszczynski 2007). On 
balance, there is an accumulating level of evidence that TGF-β1  is  upregulated 
in asthmatic airways, and that there is also upregulation of TGF- β1 signalling 
pathways (Bossé & Rola-Pleszczynski 2007). It would appear that TGF-β1 
plays a role in the initial recruitment of antigen presenting cells (APCs) and 
mast cells to the airways, and that subsequently TGF-β1 is involved in matrix 
deposition and airway remodelling (Bossé & Rola-Pleszczynski 2007). Some 
authors have suggested a relationship between TGF-β1 expression and severe 
asthma (Al-Alawi et al. 2014). Its role in allergic rhinitis, however, remains 
unresolved, and the balance between its pro- inflammatory and anti-
inflammatory effects has not received enough attention to warrant firm 
conclusions (Salib & Howarth 2009). 
 
The TGF-β1 gene is located on chromosome 19q13, a region that has been 
associated with allergic asthma and mite sensitivity (Che et al. 2014). Several 
studies (Grainger et al. 1999; Hobbs et al. 1998) have suggested an SNP at 
position 509 (509A>G) as a functional polymorphism, which influences 
circulating levels of TGF- β1. Some studies (Salam et al. 2007; Pulleyn et al. 
2001; Bandaru et al. 2015) have shown an association between the T allele and 
asthma, whilst others (Heinzmann et al. 2005; MAK et al. 2006) have not been 
able to establish any association. A recent meta-analysis (Che et al. 2014) 






IL-10 is a predominantly anti-inflammatory protein produced by a wide variety 
of cells (Moore et al. 2001; Sabat et al. 2010). Its primary targets appear to be 
monocytes and macrophages, although there is evidence of effects on T and B 
lymphocytes, mast cells, eosinophils and neutrophils, amongst others (Sabat et 
al. 2010). The gene for IL-10 resides on chromosome 1 (Sabat et al. 2010), and 
it encodes a 178 amino acid protein which is released by almost all leukocytes 
(Sabat  et al. 2010). Human IL-10 is a homodimer that is comprised of 2 non-
covalently bonded monomers (Sabat et al. 2010). 
 
The IL-10 receptor comprises of 2 chains, IL-10R1 and IL-10R2 (Moore et al.  
2001). IL-10 signalling is achieved mainly via the Jak-Stat pathway (Moore et 
al. 2001; Sabat et al. 2010). IL-10 suppresses all pro-inflammatory 
functions of the monocyte/macrophage system, as well as enhancing the 
inhibitory, tolerance- inducing, and ‘scavenger’ functions of these cells (Sabat 
et al. 2010). IL-10  is thought to play an important role in the development of 
oral tolerance (Battaglia et  al. 2004). Its role in response to respiratory viral 
infections is rather more complicated. Decreased levels of IL-10 synthesis are 
thought to be beneficial in the early stages of infection, where high levels of 
IL-10 have been associated with higher levels of viral infiltration(Zdrenghea 
et al. 2015), however IL-10 is important in attenuating the inflammatory 
response in the late stages of infection(Zdrenghea et al. 2015). IL-10 
production has been reported as being both increased and reduced in 
asthmatics, possibly representing different clinical phenotypes of disease 
(Heaton et al. 2005). 
 
Several polymorphisms in the IL-10 gene have been associated with allergic 
disease. A recent meta-analysis (Zheng et al. 2014) found that the AA genotype 
at position 1082, as well as the presence of the A allele at position 592, were 
both significantly associated with asthma susceptibility. Another meta-analysis 
(Nie et al. 2012) found a 27% increased asthma risk in people with the AA 
genotype at position 1082, as well as a significant asthma risk in those with the 
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A allele at position 592. However, another meta-analysis (Hyun et al. 2013) 
produced evidence which contradicts the others, in that they found no 
association between the 592A>C polymorphism, and an increased asthma risk 
in carriers of the G allele in position 1082. 
 
Associations between other atopic diseases and IL-10 polymorphisms are 
much less well studied. A small study (Sohn et al. 2007) suggested an 
association between the A allele at position 592 and blood eosinophil counts 
in children with atopic dermatitis. In addition, a recent Brazilian study (Jacob 
et al. 2013) suggested an association between children homozygous for the G 
allele at position 1082 and persistence of cow’s milk protein allergy. 
 
IL-4 and IL-4R 
IL-4 is a pleiotropic cytokine, with critical importance in allergic sensitization 
as well as both the early and late phases of the allergic inflammatory response 
(Maes et al.  2012). It binds to high affinity receptors on many haematopoietic 
and non-haematopoietic cells, with wide ranging effects (Maes et al. 2012), the 
best studied  of which include stimulating naïve CD4+ T cells to become TH2 
lymphocytes (Paul 2015), and inducing B cells to undergo isotype class 
shifting to produce IgE (Paul 2015). 
 
The IL-4 gene, which has been mapped to chromosome 5q31, comprises of 4 
exons and can be spliced, resulting in at least 2 protein product isoforms. 
Variants include either a full-length isoform translated from all 4 exons, or an 
alternative, IL-4δ2, which is translated from exons 1, 3 and 4 (Luzina et al. 
2012). Although their functions seem to overlap, the full significance of this 
variable splicing remain to be fully studied (Luzina et al. 2012). Two IL-4 
receptors exist in man, type I and type II (Paul 2015). Type I receptors 
comprise of the IL-4Rα chain as well as the IL-2Rγc chain (Paul 2015), whilst 
type II receptors comprise the IL-4Rα chain as well as the IL-13Rα1 chain 
(Paul 2015). This receptor homology explains some of the commonality of 
function between IL-4 and IL-13 (Paul 2015; Luzina et al. 2012; Maes et al. 
2012), however the two proteins utilize the type II receptors quite differently, 
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which explains how they both have unique functions (Paul 2015; Maes et al. 
2012). Haematopoietic cells usually express between 20-300 type I receptors 
per cell (Luzina et al. 2012), however activation of lymphocytes (for example, 
by bacterial lipopolysaccharide) increases the number of type I receptors by 5-
10 fold (Luzina et al. 2012). Binding of IL-4 to type I receptors induces 
phosphorylation of STAT6 (Paul 2015), which, when activated, translocates to 
the cell nucleus and influences synthesis of inflammatory mediators (Luzina et 
al. 2012). 
 
Effects of IL-4 secretion are numerous, and include stimulation of naïve CD4+ 
T cells to differentiate into TH2 lymphocytes, induction of B cell isotype 
switching to produce IgE. In addition, in allergic airway disease, IL-4 induces 
recruitment of eosinophils and mast cells into the airway (Maes et al. 2012), 
and promotes  bronchial hyper-responsiveness (Maes et al. 2012). In addition, 
and in conjunction with IL-13, IL-4 promotes structural airway remodelling 
(Paul 2015; Maes et al. 2012; Luzina et al. 2012). Various polymorphisms in 
the IL-4 and IL-4R〈 gene have been studied in relation to allergic diseases. A 
recent meta-analysis found an association between the TT genotype at position 
589 in the IL-4 gene and asthma in both Caucasian and Asian populations, but 
not in those of African-American descent (Nie et al. 2013). Similar results in 
both Asian and Caucasian people, and in adults as well as in children, were 
found in another meta-analysis (Yang 2013). This meta-analysis also looked at 
a polymorphism in position 33 of the IL-4 gene, and showed an association 
between the TT genotype and asthma risk (Yang 2013). Although there is 
much less literature regarding association between IL-4 polymorphisms and 
allergic rhinitis, one meta- analysis found weak associations between both of 
the above polymorphisms and allergic rhinitis risk (Li et al. 2014). 
 
The IL-4R〈 chain also has several polymorphisms of interest in relation to 
asthma and allergic disease. Two polymorphisms, 223A>G, which results in 
an amino acid substitution in position 50 (50Ile(A)/Val(G)) and 1727A>G, 
resulting in amino acid substitution in position 551 (551Gln(A)/Arg(G)), have 
been shown to be associated with asthma in a meta-analysis of Han Chinese 
people (Huang et al. 2015). These findings have been confirmed in another 
77
 
meta-analysis (Nie et al. 2013), suggesting  a dominant inheritance model for 
223A>G and recessive for 1727A>G. 
 
IL-8 
Interleukin-8 is a potent pro-inflammatory cytokine. It possesses 
chemoattractant properties, mostly towards neutrophils, but also T-
lymphocytes, monocytes and basophils (Harada et al. 1994). It also causes 
neutrophil activation and release of lysosomal enzymes (Harada et al. 1994) 
and adhere to endothelial cells. In response to lipopolysaccharide, live bacteria, 
and other early pro-inflammatory cytokines (such as TNF-〈 and IL-1), IL-8 is 
synthesized by a wide variety of cells, but principally by the 
monocyte/macrophage system (Remick 2005). Its effects are mediated via two 
specific IL-8 receptors, IL-8RA and IL-8RB, members of the “seven spanners” 
receptor family (so termed because they cross the cell membrane seven times) 
(Remick 2005). The IL-8 receptor is coupled to a g-protein and signals are 
transmitted through a g-protein second messenger system (Remick 2005; 
Cheong et al. 2006). 
 
IL-8 is thought to be an important inflammatory cytokine and chemokine in 
asthma. Increased IL-8 levels have been found in the sputum of asthmatics 
prior to an exacerbation (Cheong et al. 2006), and levels in sputum and BAL 
fluid have been found to correspond to asthma severity (Nakagome et al. 2012; 
Hosoki et al. 2015). In addition, a recent study correlated IL-8 levels in BAL 
fluid and FEV1 in asthmatic patients (Hosoki et al. 2015). 
 
Despite strong evidence that IL-8 is an important cytokine in the inflammatory 
process of asthma, there is a paucity of literature confirming associations 
between genetic polymorphisms in the IL-8 gene and allergic disease. A 
polymorphism in position 781 has been associated with asthma in people of 
Caucasian origin (Heinzmann et al. 2004), however this data has not been 





STAT6 is a member of the signal transducers and activators of transcription  
(STATs) family (Walford & Doherty 2013). STATs undergo tyrosine 
phosphorylation by Janus kinases (JAKs) in response to appropriate cytokine 
exposure (Walford & Doherty 2013). Interaction of IL-4 and IL-13 with the 
IL-4R〈 sub-unit results in a common STAT6-mediated signalling pathway that 
is a central part of the TH2 immune response (Walford & Doherty 2013). Once 
phosphorylated, STAT6 is transported to the cell nucleus, where it regulates 
expression of various genes of importance in the allergic and parasitic immune 
response (Walford & Doherty 2013; Wurster et al. 2000). 
 
STAT6 is therefore responsible for mediating the many features of the TH2 
allergic inflammatory response initiated by IL-4 and IL-13, depending on the 
type of cell in which it is acting. In T-lymphocytes, STAT6 is responsible for 
TH2 differentiation and proliferation (Goenka & Kaplan 2011). In B-
lymphocytes, STAT6 influences IgE and IgG1 isotype switching, and 
expression of certain cell surface markers necessary for antigen presentation 
by B cells, thereby directly impacting circulating levels  of  IgE  (Goenka  &  
Kaplan  2011).  STAT6  is  also  an  important signaling molecule in other cells, 
including eosinophils, the monocyte/macrophage system, the mammary 
glands, lung epithelium and skin (Stokes et al. 2015; Goenka & Kaplan 2011). 
Evidence for STAT6 being a central driver of allergic inflammation comes 
from murine models that show that STAT6 deficient mice show greatly 
attenuated predisposition to developing, amongst others, allergic airway 
disease, food allergies, atopic dermatitis and eosinophilic oesophagitis 
(Goenka & Kaplan 2011). 
 
Because of the likely contribution of STAT6 to allergic inflammation, several 
SNPs have been studied in order to establish an association with allergic 
disease. The results have been conflicting, with several studies (Amoli et al. 
2002; Casaca et al. 2013; Qian et al. 2014; Zhu et al. 2013) showing quite 
different results. Thus far there is no consensus in the literature regarding 
STAT6 polymorphisms and allergic disease. 
 
TLR2 and TLR4 
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Toll-like receptors (TLRs) are a type of pattern recognition receptors (PRRs) 
that recognize certain evolutionarily conserved molecular patterns common to 
pathogens, but not to multicellular organisms (Lin 2004; Yang et al. 2006). 
They are expressed in the cells of the innate immune system (Yang et al. 2006), 
and interact with certain pathogen associated molecular patterns (PAMPs) such 
as bacterial endotoxin, lipoteichoic acid, and viral associated double-stranded 
RNA (dsRNA) (Lin 2004). This interaction causes release of pro-inflammatory 
cytokines such as TNFα, IFNγ and IL-1,6 and 12 (Yang et al. 2006), causing 
activation of the innate immune  system and direct microbial killing (Lin 
2004), promote regulation of the adaptive immune system via (amongst other 
things) differentiation and proliferation of TH1 lymphocytes (Yang et al. 2006), 
and assist in the induction of immune tolerance (Lin 2004). 
 
Two of these TLRs, TLR2 and TLR4, are of particular interest in allergy and 
asthma. Although they both have similar actions, they recognize different 
PAMPs  (Lin 2004). TLR2 recognizes bacterial peptidoglycan and bacterial 
lipoprotein, whereas TLR4 recognizes lipopolysaccharide and lipoteichoic 
acid (Lin 2004). Evidence for associations between TLR polymorphisms and 
allergic disease is still accumulating (Yang et al. 2006), and their effect may 
be environment dependent. 
 
In keeping with the ‘hygiene hypothesis’, the finding of a decreased prevalence 
of asthma and allergic disease in children raised on animal farms has led to a 
theory  that exposure to microbial products alters the immune response away 
from TH2 mediated inflammation (Eder et al. 2004). TLRs, as a vital part of 
the innate immune response to microbes, have garnered much interest as 
playing a role in this immune modification. Various studies have suggested a 
role in, amongst other things, the development of oral tolerance (Tunis & 
Marshall 2014), the development of TH1 cutaneous sensitization (Jin et al. 
2009), as well as directly triggering TH1 effector functions (Imanishi et al. 
2007). Furthermore, altered expression of TLRs has been demonstrated in 
allergic and non-allergic rhinitis (Vanhinsbergh et al. 2007) as well as in atopic 




Although results from several studies have been heterogeneous, a recent study 
suggested an association for the TLR2 2258G>A (Arg753Gln) polymorphism 
with asthma and atopy severity (Hussein et al. 2012). In contrast, a Japanese 
study (Noguchi et al. 2004) found no link between TLR polymorphisms and 
asthma or atopy. 
 
The evidence for an association between the TLR4 896 A>G (Asp299Gly) 
polymorphism and allergic disease is similarly conflicting. Although there is 
some evidence for an association between this polymorphism and severity of 
asthma and allergic rhinitis (Yang et al. 2004), several studies (Bahrami et al. 
2014; Sinha et al. 2014) including a recent meta-analysis (Yao et al. 2014), 
have failed to show an association between the polymorphism and the 






Al-Alawi, M., Hassan, T. & Chotirmall, S.H., 2014. Transforming growth 
factor β and severe asthma: A perfect storm. Respiratory Medicine, 
108(10), pp.1409– 1423. Available at: 
http://dx.doi.org/10.1016/j.rmed.2014.08.008. 
Amoli, M.M. et al., 2002. Polymorphism in the STAT6 gene encodes risk 
for nut allergy. Genes and Immunity, 3(4), pp.220–224. Available at: 
http://www.nature.com/doifinder/10.1038/sj.gene.6363872. 
Bahrami, H. et al., 2014. Lack of association between toll like receptor-2 & 
toll like receptor-4 gene polymorphisms and Iranian asthmatics risk or 
features. HOAJ Biology, 3(1), p.1. Available at: 
http://www.hoajonline.com/hoajbiology/2050- 0874/3/1. 
Baldini, M. et al., 1999. A Polymorphism in the 5’ flanking region of the 
CD14 gene is associated with circulating soluble CD14 levels and with 
total serum immunoglobulin E. American Journal of Respiratory Cell 
and Molecular Biology, 20(5), pp.976–983. 
Bandaru, S. et al., 2015. Association of Transforming Growth Factor-Beta 1 
Promoter Variant -509 C/T with Bronchial Asthma in South Indian 
Population. Inflammation, 38(1), pp.409–414. Available at: 
http://link.springer.com/10.1007/s10753-014-0045-5. 
Barnes, K.C., 2010. Genomewide association studies in allergy and the 
influence of ethnicity. Current Opinion in Allergy and Clinical 
Immunology, 10(5), pp.427– 433. 
Battaglia, M. et al., 2004. IL-10-Producing T Regulatory Type 1 Cells and 
Oral Tolerance. Annals of the New York Academy of Sciences, 1029(1), 
pp.142–153. Available at: 
http://doi.wiley.com/10.1196/annals.1309.031. 
Bertics, P., Koziol, C. & Wiepz, G., 2014. Signal transduction. In 
Middleton’s Allergy: Principles and Practice - 8th ed. pp. 184-
202. 
Billiau, A. & Matthys, P., 2009. Interferon-©: A historical perspective. 
Cytokine and Growth Factor Reviews, 20(2), pp.97–113. 
Bleecker, E.R. et al., 2006. Salmeterol response is not affected by beta2-
82
adrenergic receptor genotype in subjects with persistent asthma. The 
Journal of Allergy and Clinical Immunology, 118(4), pp.809–816. 
Bossé, Y. & Rola-Pleszczynski, M., 2007. Controversy surrounding the 
increased expression of TGF beta 1 in asthma. Respiratory Research, 
8, p.66. 
Casaca, V.I. et al., 2013. STAT6 polymorphisms are associated with 
neonatal regulatory T cells and cytokines and atopic diseases at 3 years. 
Allergy, 68(10), pp.1249–58. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24053457. 
Che, Z. et al., 2014. The association between the C-509T and T869C 
polymorphisms of TGF-β1 gene and the risk of asthma: A meta-analysis. 
Human Immunology, 75(2), pp.141–150. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0198885913005715. 
Chen, W. et al., 2004. Functional effect of the R110Q IL13 genetic variant 
alone and in combination with IL4RA genetic variants. The Journal of 
Allergy and Clinical Immunology, 114(3), pp.553–560. 
Cheong, H.S. et al., 2006. Polymorphisms in interleukin 8 and its receptors 
(IL8, IL8RA and IL8RB) and association of common IL8 receptor 
variants with peripheral blood eosinophil counts. Journal of Human 
Genetics, 51(9), pp.781– 787. 
Contopoulos-Ioannidis, D.G., Manoli, E.N. & Ioannidis, J.P., 2005. Meta-
analysis of the association of beta2-adrenergic receptor polymorphisms 
with asthma phenotypes. The Journal of Allergy and Clinical 
Immunology, 115(5), pp.963– 972. 
Corren, J., 2013. Role of interleukin-13 in asthma. Current Allergy and 
Asthma Reports, 13(5), pp.415–420. 
Dorman, S.E. et al., 1999. Viral infections in interferon-gamma receptor 
deficiency. The Journal of Pediatrics, 135(5), pp.640–643. 
Dorman, S.E. & Holland, S.M., 2000. Interferon-γ and interleukin-12 
pathway defects and human disease. Cytokine and Growth Factor 
Reviews, 11(4), pp.321–333. 
Eder, W. et al., 2004. Toll-like receptor 2 as a major gene for asthma in 
children of European farmers. The Journal of Allergy and Clinical 
83
 
Immunology, 113(3), pp.482–488. 
Gao, P.S. et al., 1999. Nonpathogenic common variants of IFNGR1 and 
IFNGR2 in association with total serum IgE levels. Biochemical and 
Biophysical Research Communications, 263(2), pp.425–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10491309. 
Goenka, S. & Kaplan, M.H., 2011. Transcriptional regulation by STAT6. 
Immunologic Research, 50(1), pp.87–96. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3107597&
tool=pmc entrez&rendertype=abstract. 
Grainger, D.J. et al., 1999. Genetic control of the circulating concentration of 
transforming growth factor type beta1. Human Molecular Genetics, 
8(1), pp.93– 97. 
Hall, I.P., 1996. Beta 2 adrenoceptor polymorphisms: are they clinically 
important? Thorax, 51(4), pp.351–353. Available at: 
http://thorax.bmj.com/cgi/doi/10.1136/thx.51.4.351. 
Hall, I.P. & Sayers, I., 2007. Pharmacogenetics and asthma: false hope 
or new dawn? The European Respiratory Journal, 29(6), 
pp.1239–1245. 
Harada, a et al., 1994. Essential involvement of interleukin-8 (IL-8) in acute 
inflammation. Journal of Leukocyte Biology, 56(5), pp.559–564. 
Heaton, T. et al., 2005. An immunoepidemiological approach to 
asthma: identification of in-vitro T-cell response patterns 
associated with different wheezing phenotypes in children. 
Lancet, 365, pp.142–149. 
Heinzmann, A. et al., 2004. Association study suggests opposite effects of 
polymorphisms within IL8 on bronchial asthma and respiratory 
syncytial virus bronchiolitis. Journal of Allergy and Clinical 
Immunology, 114(3), pp.671–676. 
Heinzmann, A. et al., 2000. Genetic variants of IL-13 signalling and human 
asthma and atopy. Human Molecular Genetics, 9(4), pp.549–559. 
Heinzmann, A. et al., 2005. Polymorphisms of the TGF-β1 gene are not 
associated with bronchial asthma in Caucasian children. Pediatric 




Hersberger, M. et al., 2010. Association of STR polymorphisms in CMA1 
and IL-4 with asthma and atopy: the SAPALDIA cohort. Human 
Immunology, 71(11), pp.1154–1160. 
Hobbs, K. et al., 1998. Interleukin-10 and Transforming Growth Factor-á 
promotor polymorphismen in allergies and asthma. American Journal 
of Respiratory and Critical Care Medicine, 158, pp.1558–1562. 
Holloway, J.W. & Yang, I.A., 2005. Beta2-Adrenergic receptor 
polymorphism and asthma: true or false? The Journal of Allergy and 
Clinical Immunology, 115(5), pp.960–962. 
Hosoki, K. et al., 2015. Analysis of a Panel of 48 Cytokines in BAL Fluids 
Specifically Identifies IL-8 Levels as the Only Cytokine that 
Distinguishes Controlled Asthma from Uncontrolled Asthma, and 
Correlates Inversely with FEV1 M. Moser, ed. PLOS ONE, 10(5), 
p.e0126035. Available at: 
http://dx.plos.org/10.1371/journal.pone.0126035. 
Hossny, E.M. et al., 2008. Association of polymorphisms in the mast cell 
chymase gene promoter region (-1903 g/A) and (TG)n(GA)m repeat 
downstream of the gene with bronchial asthma in children. Journal of 
Investigational Allergology & Clinical Immunology, 18(5), pp.376–
381. 
Huang, Z.Y. et al., 2015. Association of the IL-4R Q576R polymorphism and 
asthma in the Chinese Han population: a meta-analysis. Genetics and 
Molecular Research    : GMR, 14(1), pp.2900–11. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25867440. 
Hussein, Y.M. et al., 2012. Toll-like receptor 2 and Toll-like receptor 4 
polymorphisms and susceptibility to asthma and allergic rhinitis: 
A case– control analysis. Cellular Immunology, 274(1-2), pp.34–
38. Available at: http://dx.doi.org/10.1016/j.cellimm.2012.02.006. 
Hyun, M.H. et al., 2013. Interleukin-10 Promoter Gene 
Polymorphisms and Susceptibility to Asthma: A Meta-
Analysis. PLoS ONE, 8(1). 
Imanishi, T. et al., 2007. Cutting edge: TLR2 directly triggers Th1 effector 
85
 
functions. Journal of Immunology (Baltimore, Md.    : 1950), 178(11), 
pp.6715– 6719. 
Israel, E. et al., 2004. Use of regularly scheduled albuterol treatment in 
asthma: genotype-strati ed, randomised, placebo-controlled cross-over 
trial. The Lancet, 364, pp.1505–1512. 
Iwanaga, T. et al., 2004. Polymorphism of the mast cell chymase gene 
(CMA1) promoter region: lack of association with asthma but 
association with serum total immunoglobulin E levels in adult atopic 
dermatitis. Clinical and Experimental Allergy, 34(7), pp.1037–1042. 
Jacob, C. et al., 2013. Interleukin 10 (IL10) and transforming growth 
factor β1 (TGFβ1) gene polymorphisms in persistent IgE-mediated 
cow’s milk allergy. Clinics, 68(7), pp.1004–1009. Available at: 
http://clinics.org.br/article.php?id=1129. 
Jin, H. et al., 2009. Toll-like receptor 2 is important for the TH1 response 
to cutaneous sensitization. The Journal of Allergy and Clinical 
Immunology, 123(4), pp.875–882.e1. Available at: 
http://dx.doi.org/10.1016/j.jaci.2009.02.007. 
Johnson, M., 2006. Molecular mechanisms of beta(2)-adrenergic receptor 
function, response, and regulation. The Journal of Allergy and Clinical 
Immunology, 117(1), pp.18–24; quiz 25. 
Johnson, M., 1998. The beta-adrenoceptor. American Journal of 
Respiratory and Critical Care Medicine, 158(5 Pt 3), pp.S146–53. 
Kedda, M.A. et al., 2005. The CD14 C-159T polymorphism is not 
associated with asthma or asthma severity in an Australian adult 
population. Thorax, 60(3), pp.211–214. 
Khoo, S.K. et al., 2004. Associations of the IL12B promoter 
polymorphism in longitudinal data from asthmatic patients 7 to 42 
years of age. The Journal of Allergy and Clinical Immunology, 
113(3), pp.475–481. 
Koppelman, G.H. et al., 2001. Association of a promoter polymorphism of 
the CD14 gene and atopy. American Journal of Respiratory and Critical 
Care Medicine, 163(4), pp.965–969. 
Lange, J. et al., 2005. CT genotype of promotor polymorphism C159T in 
86
 
the CD14 gene is associated with lower prevalence of atopic dermatitis 
and lower IL-13 production. Pediatric Allergy and Immunology, 16(5), 
pp.456–457. 
Leung, T.F. et al., 2003. The C-159T polymorphism in the CD14 promoter is 
associated with serum total IgE concentration in atopic Chinese children. 
Pediatric Allergy and Immunology, 14(4), pp.255–260. 
Li, Z. et al., 2014. Association between promoter polymorphisms of 
interleukin-4 gene and allergic rhinitis risk: a meta-analysis. Journal of 
Huazhong University of Science and Technology [Medical Sciences], 
34(3), pp.306–313. Available at: 
http://link.springer.com/10.1007/s11596-014-1275-3. 
Lin, Z., 2004. Toll-like receptors    : function and roles in asthma. Chinese 
Medical Journal, 117(11), pp.1709–1715. 
Liu, Z., Li, P. & Wang, J., 2014. A Meta-Analysis of IL-13 Polymorphisms 
and Pediatric Asthma Risk. Medical Science Monitor, 20, pp.2617–
2623. Available at: 
http://www.medscimonit.com/abstract/index/idArt/891017. 
Luzina, I.G. et al., 2012. Regulation of inflammation by interleukin-4: a 
review of “alternatives.” Journal of Leukocyte Biology, 92(4), pp.753–
764. Available at: 
http://www.jleukbio.org/cgi/doi/10.1189/jlb.0412214. 
Maes, T., Joos, G.F. & Brusselle, G.G., 2012. Targeting Interleukin-4 in 
Asthma: Lost in Translation? American Journal of Respiratory Cell 
and Molecular Biology, 47(3), pp.261–270. Available at: 
http://www.atsjournals.org/doi/abs/10.1165/rcmb.2012-0080TR. 
Mak, J. et al., 2006. Analysis of TGF-β1 gene polymorphisms in Hong 
Kong Chinese patients with asthma. The Journal of Allergy and 
Clinical Immunology, 117(1), pp.92–96. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0091674905019391. 
Makinde, T., Murphy, R.F. & Agrawal, D.K., 2007. The regulatory role of 
TGF-beta in airway remodeling in asthma. Immunology and Cell 
Biology, 85(5), pp.348– 356. 
Martinez, F.D. & Holt, P.G., 1999. Role of microbial burden in aetiology of 
87
 
allergy and asthma. The Lancet, 354 Suppl , pp.SII12–I15. 
Matsuda, A. et al., 2007. Genetic polymorphisms in the promoter of the 
interferon gamma receptor 1 gene are associated with atopic 
cataracts. Investigative Ophthalmology & Visual Science, 48(2), 
pp.583–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17251453. 
Moore, K.W. et al., 2001. Interleukin -10 and the Interleukin -10 receptor. 
Molecular and Cellular Biology, 1(1), pp.683–765. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11244051. 
Morahan, G. et al., 2002. Association of IL12B promoter 
polymorphism with severity of atopic and non-atopic asthma in 
children. The Lancet, 360(9331), pp.455–459. 
Nakagome, K., Matsushita, S. & Nagata, M., 2012. Neutrophilic 
inflammation in severe asthma. International Archives of Allergy and 
Immunology, 158(SUPPL. 1), pp.96–102. 
Nie, W. et al., 2013. Association between Interleukin-4 Receptor    α Chain 
(IL4RA) I50V and Q551R Polymorphisms and Asthma Risk: An 
Update Meta-Analysis. PLoS ONE, 8(7). 
Nie, W. et al., 2014. Interferon Gamma Polymorphism Is Associated with 
Asthma Risk    : A Meta-Analysis. Journal of Investigational 
Allergology & Clinical 
Immunology, 24(5), pp.324–330. 
Nie, W. et al., 2012. Interleukin-10 promoter polymorphisms and asthma 
risk: A meta-analysis. Cytokine, 60(3), pp.849–855. Available at: 
http://dx.doi.org/10.1016/j.cyto.2012.08.023. 
Nie, W. et al., 2013. The interleukin-4 -589C/T polymorphism and the risk of 
asthma: a meta-analysis including 7,345 cases and 7,819 controls. Gene, 
520(1), pp.22–29. 
Noguchi, E. et al., 2004. An association study of asthma and total serum 
immunoglobin E levels for Toll-like receptor polymorphisms in a 
Japanese population. Clinical and Experimental Allergy, 34(2), pp.177–
83. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14987294. 
Panzer, R. et al., 2014. TLR2 and TLR4 expression in atopic dermatitis, 
88
 
contact dermatitis and psoriasis. Experimental Dermatology, 23(5), 
pp.364–366. 
Paul, W.E., 2015. History of interleukin-4. Cytokine, 75(1), pp.3–7. 
Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S1043466615000599. 
Pulleyn, L.J. et al., 2001. TGFβ1 allele association with asthma severity. 
Human Genetics, 109(6), pp.623–627. Available at: 
http://link.springer.com/10.1007/s00439-001-0617-y. 
Qian, X. et al., 2014. Association of STAT6 variants with asthma risk: A 
systematic review and meta-analysis. Human Immunology, 75(8), 
pp.847–853. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0198885914001712. 
Randolph, A.G. et al., 2004. The IL12B gene is associated with asthma. 
American Journal of Human Genetics, 75(4), pp.709–715. 
Remick, D.G., 2005. Interleukin-8. Critical Care Medicine, 33(Suppl), 
pp.S466– S467. Available at: 
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpa
ge&an= 00003246-200512001-00021. 
Rylander, R. & Michel, O., 2005. Organic dust induced inflammation - Role 
of atopy and TLR-4 and CD14 gene polymorphisms. American Journal 
of Industrial Medicine, 48(4), pp.302–307. 
Sabat, R. et al., 2010. Biology of interleukin-10. Cytokine and Growth 
Factor Reviews, 21(5), pp.331–344. 
Sackesen, C. et al., 2011. The effect of CD14 C159T polymorphism on in 
vitro IgE synthesis and cytokine production by PBMC from children 
with asthma. Allergy, 66(1), pp.48–57. 
Salam, M.T. et al., 2007. Transforming Growth Factor-β1 C-509T 
Polymorphism, Oxidant Stress, and Early-Onset Childhood Asthma. 
American Journal of Respiratory and Critical Care Medicine, 176(12), 
pp.1192–1199. Available at: 
http://www.atsjournals.org/doi/abs/10.1164/rccm.200704-561OC. 
Salib, R.J. & Howarth, P.H., 2009. Transforming growth factor-beta in 
allergic inflammatory disease of the upper airways: friend or foe? 
89
 
Clinical and Experimental Allergy, 39(8), pp.1128–1135. 
Schroder, K. et al., 2004. IFN Gamma: an overview of signals, 
mechanisms and functions. Journal of Leukocyte Biology, 
75(February), pp.163–189. 
Sharma, S. et al., 2005. A novel (TG)n(GA)m repeat polymorphism 254 bp 
downstream of the mast cell chymase (CMA1) gene is associated with 
atopic asthma and total serum IgE levels. Journal of Human Genetics, 
50(6), pp.276– 282. 
Sinha, S. et al., 2014. Role of TLR4 C>1196T (Thr399Ile) and TLR4 
A>896G (Asp299Gly) polymorphisms in a North Indian population 
with asthma: a case- control study. International Journal of 
Immunogenetics, 41(6), pp.463–471. 
Available at: http://doi.wiley.com/10.1111/iji.12115. 
Smith, N.L. & Denning, D.W., 2014. Clinical implications of interferon 
gamma genetic and epigenetic variants. Immunology, pp.499–511. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/25052001. 
Sohn, M.H. et al., 2007. Association of interleukin-10 gene promoter 
polymorphism in children with atopic dermatitis. The Journal of 
Pediatrics, 150(1), pp.106–8. Available at: 
http://www.sciencedirect.com/science/article/pii/S0022347606008328 
[Accessed October 11, 2015]. 
Stokes, K. et al., 2015. Cutting Edge: STAT6 Signaling in Eosinophils Is 
Necessary for Development of Allergic Airway Inflammation. The 
Journal of Immunology. Available at: 
http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1402096. 
Subramaniam, P.S., Torres, B.A. & Johnson, H.M., 2001. So many ligands, 
so few transcription factors: a new paradigm for signaling through the 
STAT 
transcription factors. Cytokine, 15(4), pp.175–187. 
Teixeira, L.K. et al., 2005. The role of interferon-gamma on immune and 
allergic responses. Memorias do Instituto Oswaldo Cruz, 100 Suppl 
(December 2004), pp.137–144. 
Tunis, M.C. & Marshall, J.S., 2014. Toll-Like Receptor 2 as a Regulator of 
90
 
Oral Tolerance in the Gastrointestinal Tract. Mediators of Inflammation, 
2014, pp.1– 7. 
Vanhinsbergh, L.J., Powe, D.G. & Jones, N.S., 2007. Reduction of TLR2 
gene expression in allergic and nonallergic rhinitis. Annals of Allergy, 
Asthma & Immunology, 99(6), pp.509–516. Available at: 
http://dx.doi.org/10.1016/S1081-1206(10)60379-1. 
Vercelli, D., 2002. The functional genomics of CD14 and its role in IgE 
responses: An integrated view. The Journal of Allergy and Clinical 
Immunology, 109(1), pp.14–21. 
Walford, H.H. & Doherty, T. a, 2013. STAT6 and lung inflammation. Jak-
Stat, 2(4), p.e25301. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3876430&to
ol=pmc entrez&rendertype=abstract. 
Wang, Z.D. et al., 2013. Association between the interleukin-4, interleukin-
13 polymorphisms and asthma: a meta-analysis. Molecular Biology 
Reports, 40(2), pp.1365–1376. 
Wechsler, M.E. et al., 2009. Effect of beta2-adrenergic receptor 
polymorphism on response to longacting beta2 agonist in asthma 
(LARGE trial): a genotype- stratified, randomised, placebo-
controlled, crossover trial. The Lancet, 374(9703), pp.1754–1764. 
Weidinger, S. et al., 2005. Association study of mast cell chymase 
polymorphisms with atopy. Allergy, 60(10), pp.1256–1261. 
Wood, P.M. et al., 2005. Inherited defects in the interferon-gamma receptor 
or interleukin-12 signalling pathways are not sufficient to cause allergic 
disease in children. European Journal of Pediatrics, 164(12), pp.741–
747. 
Wurster,  a L., Tanaka, T. & Grusby, M.J., 2000. The biology of Stat4 and 
Stat6. Oncogene, 19(2000), pp.2577–2584. 
Xu, J. et al., 2000. Major genes regulating total serum immunoglobulin E 
levels in families with asthma. American Journal of Human Genetics, 
67(5), pp.1163– 1173. 
Xu, Y. & Wang, J., 2014. Association of CD14 gene -159C / T polymorphism 
with allergic rhinitis risk    : a meta-analysis. European Archives of Oto-
91
 
Rhino- Laryngology, 271, pp.1601–1607. 
Yang, H.J., 2013. Association between the interleukin-4 gene C-589T and 
C+33T polymorphisms and asthma risk: a meta-analysis. Archives of 
Medical Research, 44(2), pp.127–135. 
Yang, I. a et al., 2006. The role of Toll-like receptors and related 
receptors of the innate immune system in asthma. Current Opinion 
in Allergy and Clinical Immunology, 6(1), pp.23–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16505608. 
Yang, I. a et al., 2004. Toll-like receptor 4 polymorphism and severity of 
atopy in asthmatics. Genes and Immunity, 5(1), pp.41–5. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/14735148. 
Yao, Y. et al., 2014. TLR4 + 896A > G (Asp299Gly) polymorphism is not 
associated with asthma    : a update meta-analysis. International Journal 
of Clinical and Experimental Medicine, 7(12), pp.5358–5361. 
Ying, X. et al., 2012. Association of interleukin-13 SNP rs1800925 with 
allergic rhinitis risk: A meta-analysis based on 1,411 cases and 3169 
controls. Gene, 506(1), pp.179–183. Available at: 
http://dx.doi.org/10.1016/j.gene.2012.06.066. 
Ying, X.J. et al., 2013. Association of interleukin-13 SNP rs20541 with 
allergic rhinitis risk: A meta-analysis. Gene, 521(2), pp.222–226. 
Available at: http://dx.doi.org/10.1016/j.gene.2013.03.088. 
Young, H.A. & Hardy, K.J., 1995. Role of interferon-gamma in 
immune cell regulation. Journal of Leukocyte Biology, 58(4), 
pp.373–381. 
Zdrenghea, M.T. et al., 2015. The role of macrophage IL-10/innate IFN 
interplay during virus-induced asthma. Reviews in Medical Virology, 
25(1), pp.33–49. Available at: 
http://doi.wiley.com/10.1002/rmv.1817. 
Zhang, G. et al., 2011. Disparity of innate immunity-related gene effects on 
asthma and allergy on Karelia. Pediatric Allergy and Immunology, 
22(6), pp.621–630. 
Zhang, G., Goldblatt, J. & LeSouef, P.N., 2008. Does the relationship 




Zhang, Y. et al., 2011. The -159C/T polymorphism in the CD14 gene and the 
risk of asthma: a meta-analysis. Immunogenetics, 63(1), pp.23–32. 
Zhao, L. & Bracken, M.B., 2011. Association of CD14 -260 (-159) C>T and 
asthma: a systematic review and meta-analysis. BMC Medical Genetics, 
12, p.93. 
Zheng, X.Y. et al., 2014. Interleukin-10 promoter 1082/-819/-592 
polymorphisms are associated with asthma susceptibility in Asians and 
atopic asthma: A meta- analysis. Lung, 192(1), pp.65–73. 
Zhu, L. et al., 2013. The Correlation Analysis of Two Common 
Polymorphisms in STAT6 Gene and the Risk of Asthma: A Meta-









The design of this study has been previously published (Levin et al. 2008; 
Levin et al. 2011), but for the purposes of this report, an overview is presented. 
A convenience sample of two hundred and eleven Xhosa children, with a mean 
age of 17 years, was obtained from a high school in Mowbray, Cape Town, 
between the months of May and September 2005. Children were identified as 
Xhosa if they indicated in their written questionnaire that both parents spoke 
Xhosa as a first language. The children completed a questionnaire modified 
from that used by the International Study of Asthma and Allergies in 
Childhood (ISAAC) regarding symptoms of asthma, eczema and rhinitis. Skin 
prick tests (SPTs) to common aeroallergens, blood samples for total IgE and 
Ascaris- specific IgE, and a modified methacholine challenge for bronchial 
hyper- responsiveness (BHR), were performed. In addition, blood samples 
were taken for genotyping of twenty-seven SNPs on sixteen distinct genes 
known or theorised to be associated with allergy and/or asthma. 
 
We aim to report on the prevalence of the alleles of these SNPs in our sample, 
and to describe associations between any of the alleles and the clinical and 
laboratory markers of allergy. In addition, several similar studies have been 
performed on populations around the world (Le Souëf, personal 
communication), which will make it possible to compare the frequency of these 
alleles in different populations. 
 
Physical Methods 
Prevalence of asthma and allergy symptoms were assessed through self-
reporting. Questionnaires, modified from those used by ISAAC regarding 
asthma, eczema and rhinitis, were administered in either English or Xhosa. The 





To evaluate BHR, a modified metacholine challenge was performed. The 
method for this challenge has been previously published (Levin et al. 2011), 
but in brief it involved the use of a handheld glass nebuliser rather than 
traditional dosimeter. This method was based on a protocol described in 1983 
(Yan et al.). The protocol was borne out of the need to devise a simple and 
rapid method to evaluate bronchial hyper-responsiveness, thus enabling 
screening of large numbers of patients in much less time than using traditional 
methods. The original study (Yan et al. 1983) showed good correlation 
between results obtained using the rapid method and those obtained using a 
traditional dosimeter. This was confirmed by our group on a small subset of 
our sample (Levin et al. 2011), however the presence of bias precluded the 
development of a fixed cutoff point. Metacholine was administered in doubling 
doses from 0.0015mg to 0.5mg, and BHR was defined as a fall in FEV1 of 
≥ 20% at any dose below the maximum dose administered. 
 
SPTs were performed to house dust mites (Dermatophagoides pteronyssinus 
and Dermatophagoides farinae), grass mix, Bermuda grass, mould mix, cat, 
dog,  German cockroach (all ALK-Abello®), egg white, milk, peanut and 
potato (all fresh extracts). SPT’s were deemed positive if wheal size was ≥3mm 
larger than the negative control. 
 
Blood was drawn for total serum IgE, as well as IgE to Ascaris. Blood was also 
drawn for genotyping, which was performed by the University of Western 
Australia. This involved isolating DNA from the blood, amplification of the 
region of interest by use of PCR primers, and then digestion of the amplified 
regions with restriction enzymes. The digested products were separated on a 
2% agarose gel and visualised under a transilluminator. Genotyping accuracy 
was confirmed by DNA sequencing a randomly selected subset of the 
population. 
 
The table below shows the SNPs genotyped in this study. As far as possible, 
we have kept to the Human Genome Variation Society (HGVS) 
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recommendations for SNP nomenclature (den Dunnen & Antonarakis 2000; 
den Dunnen et al. 2016). We used the Database of Short Genetic Variations 
(dbSNP) from  the  National Center for Biotechnology Information (NCBI) to 
verify SNP nomenclature and reference alleles for these SNPs  (Sherry  et  al.  
2001).  Six  of  the  SNPs  genotyped are on the complementary strand to the 
reference SNP obtained from dbSNP. These are marked with an asterisk in the 






Chromosomal	  location 4q13-­‐q21 4q32
SNP 592A>C 1082A>G 781C>T 2258G>A 33C>T 589C>T 2979T>G*
RS	  number rs1800872 rs1800896 rs2227306 rs5743708 rs2070874 rs2243250 rs2227284
Reference	  alleles A/C A/G C/T G/A C/T C/T A/C
Reference	  ancestral	  allele C A C G T C A
Pro-­‐Th2	  allele A A C A T T T
Gene
Chromosomal	  location
SNP 159T>C* 550C>T 1188A>C 6408delCTCTAAinsGC* 130A>G* 1112C>T 4738A>G
RS	  number rs2569190 rs5744455 rs3212227 rs17860508 rs20541 rs1800925 rs1295685
Reference	  alleles A/G C/T A/C TTAGAG/GC C/T C/T A/G
Reference	  ancestral	  allele G C A N/A C T G
Pro-­‐Th2	  allele C T N/A CTCTAA A T A
Gene TLR4 SCGB1A STAT6
Chromosomal	  location 9q32-­‐q33 11q12.3-­‐q13.1 12q13
SNP 46G>A 79G>C 56T>C 611C>T* 896A>G 38G>A 2964A>G
RS	  number rs1042713 rs1042714 rs2234711 rs1327474 rs4986790 rs3741240 rs324015
Reference	  alleles A/G C/G C/T A/G A/G A/G A/G
Reference	  ancestral	  allele G G C A A G A
Pro-­‐Th2	  allele A C C T G A G
Gene IFNG CMA1 TGFB
Chromosomal	  location 12q14 14q11.2 19q13.1
SNP 874T>A 1903G>A 223A>G 1507T>C 1727A>G 509A>G*
RS	  number rs2430561 rs1800875 rs1805010 rs1805015 rs1801275 rs1800469
Reference	  alleles A/T A/G A/G C/T A/G C/T
Reference	  ancestral	  allele T G G T G C







Fig	  1.1.	  	  List	  of	  all	  SNPs	  and	  genes	  under	  investigation.	  Reference	  data	  obtained	  from	  NCBI	  SNP	  database	  (dbSNP).	  For	  several	  SNPs,	  the	  study	  alleles	  are	  located	  on	  the	  complementary	  








All statistical analysis was completed by using R (R Foundation for Statistical 
Computing, Vienna, Austria; https://www.R-project.org). In total, there were 
eighteen objective (skin prick or blood test) markers and ten clinical markers 
of allergy. In addition, we genotyped the sample for twenty-seven different 
known genetic polymorphisms on sixteen distinct genes. 
 
We assessed genotype and allele distribution (using the genetics package from 
R), the number of individuals successfully genotyped and performed an exact 
test of Hardy-Weinberg equilibrium on all SNPs. We used the D’ statistic to 
assess LD and we also estimated all possible haplotype frequencies (using the 
haplo.stats package from R). 
 
We looked for association between the twenty-seven SNPs and clinical and 
laboratory markers of allergy. We elected to set our significance level to a P-
value <0.05 and not to correct for multiple testing, for several reasons. Firstly, 
there is no single established method of correcting for multiple testing (Hsueh 
et al. 2003; Farcomeni 2008). In addition, because this study is the first to 
explore these polymorphisms in a Black African population, we felt that the 
error of not reporting  a positive association (missing a true positive 
association) would be more serious than reporting a false positive association. 
All associations were  corrected  for several exposures (age, gender, cat, dog 
or farm animal exposure, cigarette or fire smoke exposure and type of 
accommodation), which were added to the association models as fixed effects. 
 
We modelled genotype (three genotypes, conferring two degrees of freedom) 
and additive allelic (counting the number of minor alleles to determine a ‘dose- 
response’) predictor representations of each SNP. The results guided us to find 
the best fitting model (lowest P-value) from the five possibilities: genotype, 
additive allelic, dominant, recessive and heterozygote. All P-values, effect 









The phenotypic characteristics of the sample population have been published 
previously (Levin et al. 2012; Levin et al. 2011; Levin et al. 2008), but are 
summarised below. Binary and categorical variables are reported as a number 
and percentage of positive results, and continuous variables are reported as 
medians with an interquartile range. The only continuous variables were total 
IgE and IgE to Ascaris lumbricoides. Both variables were not normally 
distributed, hence we have used median rather than mean as a marker of central 
tendency. 
 
Our sample comprised 211 individuals, of which 60% were female (n=127). 
The self-reported prevalence of asthma was 10% (n=22), whilst bronchial 
hyper- responsiveness was demonstrated in 16% (n=33). The self-reported 
prevalence of rhinitis was 49% (n=103), and the self-reported prevalence of 
eczema was 21% (n=44). As previously reported (Levin et al. 2011), there was 
poor overlap between a self-reported diagnosis of asthma, and demonstrated 
bronchial hyper- responsiveness, with only 40% (n=8) of individuals reporting 
symptoms of asthma demonstrating bronchial hyper-responsiveness. Asthma 
was strongly associated with eczema and positive aeroallergen skin prick tests, 
whereas bronchial hyper- responsiveness was strongly associated with positive 
aeroallergen skin prick tests, and weakly associated with rhinitis. Total serum 
IgE levels were associated with atopy and IgE to Ascaris lumbricoides (Levin 
et al. 2008). IgE to Ascaris lumbricoides was strongly associated to 
aeroallergen sensitization and bronchial hyper-responsiveness, but not to 







Objective markers of allergic disease n Positive (%) 
Bronchial hyper-responsiveness 206 33(16) 
Blood markers of allergic disease n Median (IQR) 
Total IgE 210 107 kU/l (51-294) 
Ascaris IgE 208 0 kU/l (0-0.45) 
Skin tests n Positive (%) 
Any positive SPT 211 72(34) 
derp 210 51(24) 
derf 210 48(23) 
Any positive house dust mite SPT 211 55(26) 
European grass 210 11(5) 
Bermuda grass 210 9(4) 
Any positive grass SPT 211 13(6) 
Mould 210 2(1) 
Cat 210 5(2) 
Dog 210 6(3) 
Cockroach 210 37(18) 
Any positive aeroallergen SPT 211 67(32) 
Egg white 210 7(3) 
Skin tests n Positive (%) 
Milk 210 4(2) 
Peanut 210 3(1) 
Fresh potato 210 3(1) 
Any positive food SPT 211 12(6) 
Self-reported symptoms n Positive (%) 
Ever wheezed 210 73(35) 
Wheeze in last year 210 53(25) 
Self-reported diagnosis of asthma 210 22(10) 
Ever had rhinitis 210 97(46) 
Rhinitis in last year 210 93(44) 




Ever had eczema 210 55(26) 
Eczema in last year 210 55(26) 
Self-reported diagnosis of eczema 210 44(21) 
 
 
Genotype and Allele Frequencies 
The genotype and allele distribution frequencies, number successfully 
genotyped and P-values for the exact test of Hardy-Weinberg equilibrium, are 
reported below. Genotype and allele frequencies for these SNPs in the Xhosa 
population have not been reported before. These frequencies are necessary in 
order to understand and interpret the association results reported below. It also 
establishes a baseline in this population, and in order to assist further studies. 
It may be possible in the future for us to collaborate with international 
colleagues in order to compare the frequencies of PIAs in this population with 




Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
C            264 0.7 C/C    93 0.49
A           112  0.3 C/A           78 0.41
A/A           17 0.09
Number of samples typed: 187 (82%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
A          254 0.68 A/A          86 0.46
G           120 0.32 A/G          82 0.44
G/G           19 0.10
Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
C           348 0.93 C/C   161 0.86
T            28 0.07 C/T    26 0.14
T/T            1 0.01
592A>C
HWE exact p-value = 0.8634
1082A>G




HWE exact p-value = 1 
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Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
G              375 1 G/G          187 0.99
A 1 0 G/A        1 0.01
Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
T 199 0.53 T/T           51 0.27
C 177 0.47 T/C          97 0.52
C/C           40 0.21
Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
T            263 0.7 T/T           88 0.47
C          113 0.3 T/C           87 0.46
C/C           13 0.07
Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
T         354 0.94 T/T          167 0.89
G            22 0.06 T/G           20 0.11





HWE exact p-value = 0.2239
HWE exact p-value = 0.6632
2979T>G
HWE exact p-value = 0.4790
2258G>A
HWE exact p-value = 1 
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Number of samples typed: 211 (92.5%)
Genotype Frequency:
Allele n Proportion Genotype n Proportion
C          322 0.76 C/C          120 0.57
T         100 0.24 C/T          82 0.39
T/T         9 0.04
Number of samples typed: 184 (80.7%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
C           366 0.99 C/C          182 0.99
T             2 0.01 C/T           2 0.01
Number of samples typed: 213 (93.4%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
A           296 0.69 A/A          104 0.49
C           130 0.31 A/C           88 0.41
C/C          21  0.10
Number of samples typed: 187 (82%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
GC              255 0.68 GC/GC 85 0.45
TTAGAG         119 0.32 GC/TTAGAG               85 0.45
TTAGAG/TTAGAG          17 0.09
6408delCTCTAAinsGC
HWE exact p-value = 0.6137
Allele Frequency: (2 alleles)
IL12B
1188A>C
HWE exact p-value = 0.7466
CD14
HWE exact p-value = 0.3434
550C>T
HWE exact p-value = 1 
159T>C
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Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
C           267 0.71 C/C          100 0.53
T          109 0.29 C/T           67 0.36
T/T         21 0.11
Number of samples typed: 187 (82%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Allele
C           215 0.57 C/C          61 0.33
T           159 0.43 C/T           93 0.50
T/T           33 0.18
Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
G           370 0.98 G/G          182 0.97
A            6  0.02 G/A          6 0.03
Number of samples typed: 185 (81.1%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
A           368 0.99 A/A          183 0.99
G             2 0.01 A/G           2 0.01
TLR4
896A>G
HWE exact p-value = 1 
1112C>T
HWE exact p-value = 0.8816
IL13
HWE exact p-value = 1 
130A>G




Number of samples typed: 186 (81.6%)
HWE exact p-value = 0.6597
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
C           200 0.54 C/C           52 0.28
T           172 0.46 C/T           96 0.52
T/T           38 0.20
Number of samples typed: 187 (82%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
T           359 0.96 T/T         173 0.93
C            15 0.04 T/C           13 0.07
C/C            1 0.01
Number of samples typed: 211 (92.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
G           227 0.54 G/G           59 0.28
A           195 0.46 G/A         109  0.52
A/A           43 0.20
Number of samples typed: 210 (92.1%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
C           353 0.84 C/C         147 0.70
G            67 0.16 C/G           59 0.28
G/G           4 0.02
HWE exact p-value = 0.6776








Number of samples typed: 211 (92.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
G         329  0.78 G/G         127 0.60
A            93 0.22 G/A           75 0.36
A/A            9 0.04
Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
G           327 0.87 G/G          143 0.76
A           49  0.13 G/A           41 0.22
A/A            4 0.02
Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
A           310 0.82 A/A          128 0.68
T            66 0.18 A/T           54 0.29
T/T            6 0.03
874T>A
HWE exact p-value = 0.6933
38G>A
IFNG
HWE exact p-value = 1 
2964A>G




Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
G           327 0.87 G/G          142 0.76
A           49 0.13 G/A           43 0.23
A/A           3 0.02
Number of samples typed: 186 (81.6%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
G           208 0.56 G/G           59 0.32
A           164 0.44 G/A          90 0.48
A/A           37 0.20
Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
T           201 0.53 T/T           46 0.24
C           175 0.47 T/C          109 0.58
C/C           33 0.18
Number of samples typed: 188 (82.5%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Frequency
G          313 0.83 G/G          129 0.69
A            63 0.17 G/A           55 0.29
A/A           4 0.02





HWE exact p-value = 0.6104
223A>G
HWE exact p-value = 0.8817
1507T>C
HWE exact p-value = 0.0285
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Number of samples typed: 187 (82%)
Allele Frequency: (2 alleles) Genotype Frequency:
Allele n Proportion Genotype n Proportion
C           291 0.78 C/C          114 0.61
T            83 0.22 C/T           63 0.34
T/T           10 0.05
509A>G
TFGB
HWE exact p-value = 0.6771
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Linkage Disequilibrium 
Linkage disequilibrium is reported for each gene with multiple SNPs of 
































































D' Color Key 
0 0.2 0.4 0.6 0.8 
Exposures 
We adjusted all association tests for the possible confounding effect of  
environmental exposures. We corrected for six exposures (cat, dog or farm 
animal exposure, smoking cigarettes, exposure to household or other smoke on 
a regular basis, and type of accommodation). The first five exposures are 
binary, whereas accommodation was divided into four categories. The 
distributions of the exposures are given below, followed by a summary of 
associations between the exposures and our phenotypic endpoints for reference 
purposes. 
Exposures n Positive (%) 
Cat exposure 209 107(51) 
Dog exposure 209 153(73) 
Farm animal exposure 209 24(11) 
Smoker 209 34(16) 
Any smoke exposure 209 123(59) 













SPT binary 0,3357 0,7395 0,2036 0,1937 0,4039 0,6582 0,8007
derp 0,0696 0,7625 0,0688 0,3467 0,8959 0,8960 0,4844
derf 0,0424 0,8021 0,0439 0,3741 0,8352 0,9710 0,7932
housedust mite 0,0454 0,4233 0,1415 0,5874 0,6954 0,8713 0,6058
euro grass 0,5457 0,4001 0,0198 0,9707 0,7920 0,8488 0,5944
bermuda 0,4639 0,2722 0,0683 0,7470 0,9713 0,6821 0,7758
any grass 0,7880 0,2073 0,0321 0,7511 0,6619 0,8533 0,5257
mould 0,8640 0,1581 0,9729 0,2627 0,4837 0,5886 0,1669
cat 0,5803 0,9648 0,6113 0,0753 0,2663 0,8976 0,0281
dog 0,2907 0,2266 0,9526 0,7197 0,7021 0,8864 0,0160
cockroach 0,1966 0,3466 0,2080 0,1757 0,9384 0,5342 0,6006
aero  binary 0,2423 0,5105 0,0844 0,4396 0,5127 0,8323 0,7709
egg white 0,8689 0,8344 0,6531 0,3514 0,8187 0,0721 0,7805
milk 0,9384 0,6542 0,2802 0,9343 0,3207 0,0194 0,5831
peanut 0,8334 0,8365 0,0370 0,8012 0,3905 0,5886 0,3084
fresh potato 0,5706 0,3306 0,5852 0,1465 0,3130 0,1596 0,0899
foods binary 0,6669 0,4285 0,4957 0,2508 0,5822 0,2030 0,7772
ascaris2 0,2562 0,1538 0,7003 0,3791 0,8290 0,4056 0,1919
wheezeever 0,1680 0,0547 0,9137 0,8543 0,2668 0,3368 0,2800
wheezeinlastyear 0,8462 0,1636 0,4973 0,9424 0,9657 0,8104 0,3162
selfasthma 0,7533 0,4573 0,1394 0,2975 0,7017 0,6530 0,8830
rhinoever 0,1964 0,5943 0,7101 0,7520 0,7082 0,4507 0,0557
rhinolastyear 0,4078 0,3445 0,3453 0,7342 0,3127 0,2867 0,0762
selfrhino 0,1727 0,1392 0,2951 0,0947 0,0609 0,5528 0,8741
eczemaever 0,9619 0,2598 0,4977 0,9257 0,8758 0,8618 0,7978
eczemalastyear 0,7275 0,4233 0,1910 0,4265 0,8758 0,7426 0,5605
selfeczema 0,1059 0,2641 0,3911 0,0520 0,6206 0,2581 0,0631
hyper 0,0048 0,4384 0,0238 0,7119 0,5147 0,9649 0,3111




Associations Between Genotypes or Alleles and Clinical and Objective 
Markers of Allergy 
We found several significant associations between SNPs and markers of 
allergic disease. Several phenotypes, specifically skin prick tests to cat, milk, 
peanut and fresh potato, were excluded from association testing because the 
scarcity of positive results precluded meaningful interrogation. We present 
below a tabulated summary  of P-values as markers of association. All 
associations have been corrected for the identified exposures (or potential 
confounders). Those associations deemed to be possibly significant (as 
determined by having a P-value of < 0.05), were then further interrogated to 
determine the precise nature of the associations with odds ratios as a measure 
of effect sizes.  
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Genotype Wheeze ever Wheeze in last year
Self reported 
asthma Rhinitis ever










IL10 592A>C 0.5114 0.7853 0.1679 0.8566 0.9993 0.2443 0.1071 0.0425 0.7448 0.6477
IL10 1082A>G 0.0107 0.0438 0.0494 0.5855 0.8293 0.0195 0.4657 0.7023 0.7268 0.0610
IL8 781C>T 0.6327 0.5336 0.9542 0.4196 0.5995 0.4289 0.7052 0.6157 0.7868 0.4474
TLR2 2258G>A 0.3584 0.3877 0.5365 0.1757 0.2091 0.2408 0.1267 0.1693 0.1018 0.5332
IL4 33C>T 0.3509 0.2526 0.6838 0.2713 0.4909 0.1105 0.7927 0.9497 0.5169 0.0823
IL4 589C>T 0.0056 0.0182 0.5162 0.8631 0.9304 0.3202 0.0877 0.3268 0.6047 0.4141
IL4 2979T>G 0.3383 0.4205 0.3590 0.4155 0.5047 0.2763 0.7033 0.5890 0.6159 0.0285
CD14 159T>C 0.9328 0.8059 0.4223 0.8563 0.8437 0.2134 0.6982 0.4811 0.5016 0.7352
CD14 550C>T 0.3743 0.2594 0.1360 0.8762 0.7722 0.7491 0.3838 0.3252 0.2609 0.2383
IL12B 1188A>C 0.3906 0.4271 0.6850 0.4773 0.2040 0.8978 0.7330 0.4976 0.4787 0.1336
IL12B 6408delCTCTAAinsGC 0.0258 0.0866 0.0589 0.1997 0.2298 0.1757 0.4070 0.1234 0.7217 0.6190
IL13 130A>G 0.8025 0.9978 0.5846 0.3291 0.5047 0.0428 0.7102 0.8358 0.0043 0.5272
IL13 1112C>T 0.9285 0.4246 0.7155 0.8460 0.7191 0.6246 0.1329 0.0840 0.1244 0.8498
IL13 4738A>G 0.3762 0.6983 0.7470 0.1378 0.1549 0.0056 0.5692 0.6244 0.1513 0.1151
ADRB2 46G>A 0.6039 0.6795 0.4430 0.1764 0.2518 0.9285 0.4197 0.8412 0.6719 0.4565
ADRB2 79G>C 0.8263 0.3765 0.6765 0.7205 0.5642 0.2037 0.1289 0.1284 0.9600 0.3585
IFNGR1 56T>C 0.1657 0.2691 0.7378 0.4674 0.7977 0.7972 0.6223 0.3306 0.8533 0.2202
IFNGR1 611C>T 0.5723 0.5786 0.6156 0.2938 0.3783 0.3790 0.7176 0.7669 0.7261 0.7652
TLR4 896A>G 0.6507 0.4636 0.5552 0.7422 0.6514 0.5495 0.4066 0.4286 0.1863 0.0600
SCGB1A 38G>A 0.6190 0.1934 0.3331 0.1755 0.4675 0.6888 0.1146 0.4242 0.1974 0.6255
STAT6 2964A>G 0.6433 0.9305 0.1293 0.5987 0.4665 0.9674 0.1948 0.6389 0.0586 0.6493
IFNG 874T>A 0.8283 0.8812 0.6621 0.3184 0.2068 0.2092 0.1717 0.1704 0.8838 0.9861
CMA1 1903G>A 0.6982 0.8958 0.5030 0.5242 0.3884 0.8232 0.2587 0.1982 0.8991 0.1057
IL4RA 223A>G 0.3606 0.7994 0.3899 0.4119 0.6480 0.4004 0.5445 0.8631 0.7538 0.8842
IL4RA 1507T>C 0.1290 0.2506 0.7847 0.7499 0.5469 0.4907 0.0647 0.2580 0.8515 0.5700
IL4RA 1727A>G 0.0353 0.0629 0.6677 0.9659 0.9908 0.4772 0.8254 0.8560 0.9043 0.2424
TGFB 509A>G 0.2387 0.2206 0.3015 0.9815 0.9303 0.5417 0.4018 0.3099 0.3928 0.9822
Genotypes and Clinical Phenotypes
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Allele Wheeze ever Wheeze in last year
Self reported 
asthma Rhinitis ever










IL10 592A>C 0.9735 0.9938 0.3302 0.8948 0.9909 0.6146 0.0387 0.0248 0.5702 0.3655
IL10 1082A>G 0.0711 0.1812 0.9040 0.8790 0.8504 0.0075 0.7583 0.8508 0.4402 0.0273
IL8 781C>T 0.6798 0.5932 0.7595 0.3115 0.8145 0.4414 0.6631 0.7273 0.5269 0.2069
TLR2 2258G>A 0.3584 0.3877 0.5365 0.1757 0.2091 0.2408 0.1267 0.1693 0.1018 0.5332
IL4 33C>T 0.5023 0.1265 0.3962 0.1063 0.2367 0.1563 0.5747 0.8733 0.3851 0.1253
IL4 589C>T 0.0883 0.0487 0.5092 0.6449 0.8763 0.8447 0.0392 0.2122 0.3265 0.5213
IL4 2979T>G 0.1601 0.2064 0.1620 0.9834 0.8249 0.2177 0.7169 0.4811 0.9785 0.8227
CD14 159T>C 0.7424 0.5642 0.2033 0.9051 0.8516 0.3454 0.4083 0.2819 0.2402 0.4331
CD14 550C>T 0.3743 0.2594 0.1360 0.8762 0.7722 0.7491 0.3838 0.3252 0.2609 0.2383
IL12B 1188A>C 0.2428 0.2068 0.4049 0.8595 0.9817 0.6612 0.4349 0.2499 0.3541 0.9688
IL12B 6408delCTCTAAinsGC 0.3627 0.4750 0.3625 0.3272 0.2261 0.7294 0.1800 0.0415 0.4912 0.6810
IL13 130A>G 0.7354 0.9791 0.3008 0.2027 0.5526 0.6044 0.4087 0.5510 0.8563 0.4156
IL13 1112C>T 0.7109 0.2712 0.5178 0.6403 0.4280 0.4389 0.2457 0.3944 0.2657 0.5766
IL13 4738A>G 0.3762 0.6983 0.7470 0.1378 0.1549 0.0056 0.5692 0.6244 0.1513 0.1151
ADRB2 46G>A 0.9668 0.9382 0.3029 0.5313 0.4580 0.7242 0.8024 0.9018 0.4889 0.6235
ADRB2 79G>C 0.5532 0.1859 0.6708 0.4181 0.2961 0.1110 0.5346 0.6822 0.8582 0.6713
IFNGR1 56T>C 0.8233 0.9480 0.9841 0.7260 0.7618 0.6208 0.7867 0.5973 0.7712 0.3786
IFNGR1 611C>T 0.9655 0.7043 0.5207 0.1310 0.1829 0.2090 0.6293 0.6149 0.5345 0.8756
TLR4 896A>G 0.6507 0.4636 0.5552 0.7422 0.6514 0.5495 0.4066 0.4286 0.1863 0.0600
SCGB1A 38G>A 0.4260 0.0751 0.3134 0.2259 0.2892 0.4659 0.3399 0.3868 0.1610 0.6650
STAT6 2964A>G 0.3486 0.7409 0.5001 0.4872 0.2387 0.8054 0.1405 0.5141 0.0201 0.9633
IFNG 874T>A 0.5883 0.9954 0.5229 0.5264 0.2556 0.1244 0.7917 0.9934 0.6753 0.8903
CMA1 1903G>A 0.7099 0.7821 0.3070 0.2680 0.1741 0.6949 0.1535 0.1065 0.6699 0.0497
IL4RA 223A>G 0.1547 0.5548 0.1713 0.2137 0.4589 0.7768 0.4613 0.6608 0.6942 0.9457
IL4RA 1507T>C 0.0446 0.1053 0.9639 0.6867 0.6899 0.2329 0.7742 0.8140 0.7053 0.2910
IL4RA 1727A>G 0.0161 0.0244 0.8032 0.8087 0.8920 0.4274 0.5658 0.6667 0.7680 0.4826
TGFB 509A>G 0.5229 0.1940 0.2562 0.9543 0.7747 0.3185 0.3553 0.5066 0.7507 0.9998
Alleles and Clinical Phenotypes
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Genotype Any positive SPT derp derf Any positive HDM SPT cockroach
Any positive 
aeroallergen SPT
Any positive food 
SPT Total serum IgE
IL10 592A>C 0.2588 0.0303 0.0436 0.0715 0.3436 0.1815 0.4885 0.6714
IL10 1082A>G 0.0459 0.0528 0.0216 0.0110 0.2196 0.0257 0.2601 0.6663
IL8 781C>T 0.6203 0.5224 0.5675 0.6825 0.8131 0.6808 0.3661 0.9662
TLR2 2258G>A 0.3037 0.3639 0.3588 0.3345 0.5371 0.3194 0.7724 0.6329
IL4 33C>T 0.8304 0.8476 0.9843 0.9840 0.6036 0.8622 0.1776 0.3205
IL4 589C>T 0.0673 0.3028 0.2593 0.2403 0.0750 0.1043 0.8998 0.8618
IL4 2979T>G 0.2572 0.1730 0.2171 0.1994 0.6898 0.2910 0.9857 0.9966
CD14 159T>C 0.6451 0.6411 0.3216 0.4746 0.1804 0.6746 0.5745 0.2488
CD14 550C>T 0.4138 0.2578 0.2886 0.3415 0.1680 0.4516 0.8847 0.6766
IL12B 1188A>C 0.7783 0.8633 0.8928 0.8771 0.7695 0.6686 0.0656 0.6284
IL12B 6408delCTCTAAinsGC 0.7899 0.8458 0.8623 0.9092 0.8631 0.6528 0.0356 0.8539
IL13 130A>G 0.6446 0.9200 0.4856 0.7701 0.8056 0.5189 0.1046 0.9079
IL13 1112C>T 0.5292 0.4781 0.8718 0.7902 0.6244 0.7434 0.1566 0.4602
IL13 4738A>G 0.3570 0.5450 0.6166 0.5014 0.1169 0.3696 0.3983 0.0881
ADRB2 46G>A 0.0644 0.2444 0.5257 0.2418 0.1345 0.0411 0.8007 0.9320
ADRB2 79G>C 0.1787 0.4288 0.2014 0.4875 0.4667 0.3684 0.3361 0.1073
IFNGR1 56T>C 0.3188 0.2601 0.2076 0.2797 0.4044 0.2340 0.0212 0.0126
IFNGR1 611C>T 0.3166 0.1591 0.1264 0.1201 0.1631 0.3176 0.5943 0.5047
TLR4 896A>G 0.7695 0.2932 0.2610 0.2685 0.4756 0.5890 0.6851 0.9626
SCGB1A 38G>A 0.6748 0.6811 0.6274 0.7674 0.0689 0.6109 0.8364 0.6213
STAT6 2964A>G 0.5071 0.3111 0.6759 0.4186 0.5016 0.4684 0.7731 0.8226
IFNG 874T>A 0.1327 0.2453 0.4953 0.2348 0.9354 0.1966 0.0118 0.7384
CMA1 1903G>A 0.9930 0.2415 0.9836 0.9965 0.7529 0.9735 0.9435 0.2062
IL4RA 223A>G 0.2410 0.1678 0.1259 0.3095 0.5328 0.2664 0.8480 0.6499
IL4RA 1507T>C 0.9819 0.6957 0.9979 0.8277 0.7960 0.9926 0.6127 0.0822
IL4RA 1727A>G 0.4937 0.2919 0.1870 0.4176 0.6165 0.4903 0.1209 0.2666
TGFB 509A>G 0.5153 0.5100 0.7138 0.4941 0.6672 0.7656 0.2140 0.3932
Genotypes and Objective Markers of Allergic Disease
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Allele Any positive SPT derp derf Any positive HDM SPT cockroach
Any positive 
aeroallergen SPT
Any positive food 
SPT Total serum IgE
IL10 592A>C 0.1025 0.0082 0.0144 0.0220 0.1512 0.0662 0.5167 0.3715
IL10 1082A>G 0.0324 0.0301 0.0074 0.0043 0.1662 0.0103 0.6457 0.6646
IL8 781C>T 0.3779 0.2662 0.3070 0.4121 0.6020 0.4602 0.1563 0.7931
TLR2 2258G>A 0.3037 0.3639 0.3588 0.3345 0.5371 0.3194 0.7724 0.6329
IL4 33C>T 0.9698 0.8486 0.8662 0.9694 0.8979 0.9584 0.0685 0.3115
IL4 589C>T 0.0231 0.1312 0.1048 0.1036 0.0262 0.0370 0.6555 0.7696
IL4 2979T>G 0.6849 0.6536 0.4882 0.4737 0.4333 0.6087 0.9104 0.9338
CD14 159T>C 0.9145 0.5634 0.1381 0.2956 0.3826 0.4693 0.6064 0.1718
CD14 550C>T 0.4138 0.2578 0.2886 0.3415 0.1680 0.4516 0.8847 0.6766
IL12B 1188A>C 0.5700 0.8850 0.9050 0.7477 0.6324 0.4647 0.0797 0.8748
IL12B 6408delCTCTAAinsGC 0.6348 0.9890 0.6082 0.8323 0.6261 0.9067 0.0146 0.6702
IL13 130A>G 0.4550 0.6833 0.2702 0.4823 0.6132 0.3049 0.0440 0.7076
IL13 1112C>T 0.2593 0.2374 0.6083 0.5148 0.4325 0.4443 0.0841 0.2261
IL13 4738A>G 0.3570 0.5450 0.6166 0.5014 0.1169 0.3696 0.3983 0.0881
ADRB2 46G>A 0.0995 0.5658 0.3486 0.3112 0.1203 0.0527 0.5080 0.7899
ADRB2 79G>C 0.9743 0.9485 0.4761 0.8169 0.4491 0.4564 0.4977 0.1874
IFNGR1 56T>C 0.8618 0.9753 0.9766 0.7385 0.3434 0.7873 0.0736 0.0198
IFNGR1 611C>T 0.6764 0.9472 0.9656 0.8325 0.6333 0.6604 0.3076 0.9640
TLR4 896A>G 0.7695 0.2932 0.2610 0.2685 0.4756 0.5890 0.6851 0.9626
SCGB1A 38G>A 0.4025 0.4031 0.3945 0.4701 0.4697 0.3380 0.9746 0.6329
STAT6 2964A>G 0.2731 0.6173 0.3791 0.4417 0.2402 0.2785 0.6766 0.5851
IFNG 874T>A 0.4282 0.4472 0.2519 0.8259 0.8563 0.6677 0.4287 0.7869
CMA1 1903G>A 0.9087 0.2165 0.8754 0.9498 0.7699 0.8414 0.9944 0.8859
IL4RA 223A>G 0.1575 0.1274 0.2216 0.2502 0.6115 0.2318 0.5708 0.4458
IL4RA 1507T>C 0.8684 0.6648 0.9488 0.5435 0.5426 0.9241 0.6615 0.3876
IL4RA 1727A>G 0.2834 0.2024 0.0994 0.2850 0.3820 0.2761 0.3127 0.6237
TGFB 509A>G 0.2498 0.9914 0.5987 0.8152 0.4203 0.4676 0.1073 0.7792




Model Effect Type Magnitude of Effect
IL10 592A>C Positive Der p SPT additive allelelic each A allele changes odds ratio % 109 (95% CI:21 to 267)
Positive Der f SPT additive allelelic each A allele changes odds ratio % 101 (95% CI:15 to 256)
Any positive HDM SPT additive allelelic each A allele changes odds ratio % 86 (95% CI:9 to 221)
Eczema ever additive allelelic each A allele changes odds % -43 (95% CI:-66 to -3)
Eczema in past year additive allelelic each A allele changes odds % -46 (95% CI:-69 to -8)
IL10 1082A>G Any positive SPT additive allelelic each G allele changes odds ratio % -43 (95% CI:-67 to -4)
Positive Der p SPT additive allelelic each G allele changes odds ratio % -47 (95% CI:-72 to -6)
Positive Der f SPT additive allelelic each G allele changes odds ratio % -56 (95% CI:-78 to -19)
Any positive HDM SPT additive allelelic each G allele changes odds ratio % -57 (95% CI:-77 to -22)
Any positive aeroallergen SPT additive allelelic each G allele changes odds ratio % -50 (95% CI:-71 to -15)
Wheeze ever recessive GG versus AA+AG -90 (95% CI:-99 to -50)
Wheeze in past year recessive GG versus AA+AG -87 (95% CI:-99 to -31)
Self-reported rhinitis additive allelelic each G allele changes odds % -48 (95% CI:-68 to -16)
BHR additive allelelic each G allele changes odds % -54 (95% CI:-79 to -8)
IL4 589C>T Any positive SPT additive allelelic each C allele changes odds ratio % -47 (95% CI:-70 to -8)
Positive cockroach SPT additive allelelic each C allele changes odds ratio % -54 (95% CI:-78 to -9)
Any positive aeroallergen SPT additive allelelic each C allele changes odds ratio % -44 (95% CI:-68 to -3)
Wheeze ever heterozygote TC versus both homozygotes -67 (95% CI:-84 to -34)
Wheeze in past year heterozygote TC versus both homozygotes -65 (95% CI:-84 to -27)
Eczema ever additive allelelic each T allele changes odds % 79 (95% CI:3 to 215)
IL12B 6408delCTCTAAinsGC Any positive food SPT dominant model any TTAGAG vs GC/GC 305 (95% CI:31 to 1374)
Wheeze ever recessive TTAGAG/TTAGAG versus other two -87 (95% CI:-99 to -34)
Eczema in past year additive allelelic each  TTAGAG allele  changes odds % -45 (95% CI:-70 to -2)
IL13 130A>G Any positive food SPT additive allelelic each T allele changes odds ratio % -74 (95% CI:-95 to -3)
Self-reported rhinitis recessive TT versus CC+CT 192 (95% CI:6 to 807)
Self-reported eczema heterozygote CT versus CC+TT 216 (95% CI:45 to 608)
ADRB2 46A>G Any positive aeroallergen SPT recessive AA versus GG+GA 166 (95% CI:25 to 472)
IFNGR1 56T>C IgE additive allelic % change in IgE per minor allele -30 (95% CI:-48 to -6)
Any positive food SPT dominant model
All 52 with CC said had negative SPTs. So 
the effect of TT+CT (any T) is very strong.  
But could not be estimated, because the 
effect is indivisible by 0.
STAT6 2964A>G Self-reported eczema dominant GA+AA versus GG -67 (95% CI:-90 to -12)
IL4RA 1507T>C Wheeze ever additive allelelic each C allele  changes odds % 69 (95% CI:1 to 188)
IL4RA 1727A>G Wheeze ever dominant GA+AA versus GG -55 (95% CI:-79 to -8)
Wheeze in past year dominant GA+AA versus GG -58 (95% CI:-83 to -6)
Summary of Effects of Genetic Associations
120
Polymorphisms in the IL-10 gene were associated with several clinical and 
objective markers of allergy. 592A>C was associated with ever having eczema  
(additive allelic model, each A allele reduced odds ratio by 43% [95% CI: 3% 
to 66%]), as well as with having symptoms of eczema in the preceding year 
(additive allelic model, each A allele reduced odds ratio by 46% [95% CI: 8% 
to 69%]). 592A>C  was also associated with a positive Dermatophagoides 
pteronyssinus skin prick test (additive allelic model, each A allele increases 
odds ratio by 109% [95% CI: 21% to 267%]), with a positive 
Dermatophagoides farinae skin prick test (additive allelic model, each A allele 
increases odds ratio by 101% [95% CI: 15% to 256%]), as well as with any 
positive house dust mite skin prick test (additive allelic model, each A allele 
increases odds ratio by 86% [95% CI: 9% to 221%]). 
The IL-10 SNP 1082A>G was associated with a history of ever having wheeze 
(recessive model, GG reduced odds ratio by 90% [95% CI: 50% to 99%] in 
comparison to AA and AG), with a history of wheeze in the preceding year 
(recessive model, GG reduced odds ratio by 87% [95% CI: 31% to 99%] in 
comparison to AA and AG), with self-reported diagnosis of rhinitis (additive 
allelic model, each G allele reducing odds ratio by 48% [95% CI: 16% to 68%]) 
and with bronchial hyper-responsiveness (additive allelic model, each G allele 
reduced odds ratio by 54% [95% CI: 8% to 79%]). 1082A>G was also 
associated with having any positive skin prick test (additive allelic model, each 
G allele decreases odds ratio by 43% [95% CI: 4% to 67%]), with a positive 
Dermatophagoides pteronyssinus skin prick test (additive allelic model, each 
G allele reduces odds ratio by 47% [95% CI: 6% to 72%]), with a positive 
Dermatophagoides farinae skin prick test (additive allelic model, each G allele 
reduces odds ratio by 56% [95% CI: 19% to 78%]), with having any positive 
house dust mite skin prick test (additive allelic model, each G allele reduces 
odds ratio by 57% [95% CI: 22% to 77%]) and with having any positive 
aeroallergen skin prick test (additive allelic model, each G allele reduces odds 
by 50% [95% CI: 15% to 71%]). 
In addition, we found several associations between polymorphisms in genes 
that code for TH2 mediators, and markers of allergic disease. The IL-4 
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polymorphism 589C>T was associated with ever having wheeze (heterozygote 
model, TC reduces odds ratio by 67% [95% CI: 34% to 84%] in comparison 
to both homozygotes), with a history of wheeze in the preceding year 
(heterozygote model, TC reduces odds ratio by 65% [95% CI: 27% to 84%] in 
comparison to both homozygotes), as well as with a history of ever having 
eczema (additive allelic model, each T allele increases odds ratio by 79% [95% 
CI: 215% to 3%]). 589C>T was also associated with having any positive skin 
prick test (additive allelic model, each C allele reduces odds ratio by 47% [95% 
CI: 8% to 70%]), with a positive cockroach skin prick test (additive allelic 
model, each C allele reduces odds ratio by 54% [95% CI: 9% to 78%]), and 
with having any positive aeroallergen skin prick test (additive allelic model, 
each C allele reduces odds ratio by 44% [95% CI: 3% to 68%]). 
The IL-13 SNP 130A>G was associated with a self-diagnosis of allergic 
rhinitis (recessive model, TT increases odds ratio by 192% [95% CI: 6% to 
807%] in comparison to CC and CT), as well as with a self-diagnosis of eczema 
(heterozygote model, CT increases odds ratio by 216% [95% CI: 45% to 
608%] in comparison to CC and CT). In addition, 130A>G was associated with 
having any positive food allergen skin prick test (additive allelic model, each 
T allele decreases odds ratio by 74% [95% CI: 3% to 95%]). 
The IL4RA polymorphism 478T>C was associated with ever having wheeze 
(additive allelic model, each C allele increases odds ratio by 69% [95% CI: 1% 
to 188%]). Another IL4RA SNP, 551A>G, was associated with a history of  
ever having wheeze (dominant model, GA and AA reduce odds ratio by 55% 
[95% CI: 8% to 79%] in comparison to GG), as well as with a history of 
wheeze in the preceding year (dominant model, GA and AA reduce odds ratio 
by 58% [95% CI: 6% to 83%] in comparison to GG). The STAT6 
polymorphism 2964A>G was associated with a self-diagnosis of eczema 
(dominant model, GA and AA reduce odds ratio by 67% [95% CI: 12% to 
90%] in comparison to GG). 
There were, in addition, associations between genes that code for TH1 
mediators, and clinical and objective markers of allergic disease. The IL-12 
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polymorphism 6408delCTCTAAinsGC was associated with a history of ever 
having wheeze (recessive model, TTAGAG/TTAGAG reduces odds ratio by 
87% [95% CI: 34% to 99%]  in  comparison  to  TTAGAG/TCTAAGC  and  
TCTAAGC/TCTAAGC), and with a history of eczema in the preceding year 
(additive allelic model, each TCTAAGC reduces odds ratio by 45% [95% CI: 
2% to 70%]). 
6408delCTCTAAinsGC was also associated with having any positive food 
allergen skin prick test (dominant model, TTAGAG/TTAGAG and 
TTAGAG/GC increase odds ratio by 305% [95% CI: 31% to 1375%] in 
comparison to GC/GC). IFNGR 156T>C was associated with serum IgE levels 
(additive allelic model, each C allele increases serum IgE level by 30% [95% 
CI: 48% to 6%]), and with having any positive skin prick test (dominant 
model). In this specific instance, the effect size could not be estimated, as all 
55 individuals homozygous for the C allele had a negative skin prick test, 
meaning that the effect of the T allele (either TT or TC) is likely to be very 
strong. 
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DISCUSSION OF RESULTS 
Phenotypic Characteristics 
For a full discussion of the phenotypic characteristics of our sample 
population, the reader is referred to the previously published literature from 
our group (Levin et al. 2011; Levin et al. 2012; Levin et al. 2008). However, a 
few pertinent characteristics bear specific mention. 
The lack of overlap between bronchial hyper-responsiveness and self-reported 
symptoms of asthma may in part be explained by different phenotypes of 
asthma, but also highlights possible methodological concerns in the diagnosis 
of bronchial hyper-responsiveness (particularly the use of a handheld glass 
nebuliser rather than a dosimeter) and/or in the diagnosis of asthma. As 
previously mentioned, relying on self-reporting of a diagnosis of asthma rather 
than physician diagnosis may not accurately estimate the true prevalence of 
asthma (Zar et al. 2007). Additionally, language differences (most of our 
sample population do not speak English as a first language at home) and 
cultural differences in the terminology and understanding of health and disease 
may also call into question the prevalence data, as well as any significant 
associations, of our other self-reported clinical phenotypes. As these self-
reported phenotypes represent the majority of the genetic interactions 
uncovered in our study, unfortunately many of our results are limited by the 
above concerns. Assessing children at only one school may limit the 
generalizability of our findings to Xhosa speaking children as a whole. 
In addition, several objective phenotypes (specifically skin prick tests to 
European grass, Bermuda grass, mould, cat, dog, egg white, milk, peanut and 
fresh potato) showed too few positive results to perform meaningful 
interrogation of association with the SNPs. These phenotypic characteristics 




All of our SNPs were in Hardy-Weinberg Equilibrium. The genotype, allele 
and haplotype frequencies are published to establish a baseline for this 
population, and may help to guide further research. In the future it may be 
possible, as part of an international collaboration, to compare the PIA and 
haplotype frequencies against those of other populations. This may allow 
interrogation of the theory that evolutionary adaptation of the human immune 
system could influence a given population’s genetic predisposition towards 
asthma and allergic disease. Further research is required in this regard. 
 
Genotype/Phenotype Associations 
We have reported several significant associations between SNPs and markers 
of allergic disease in this population. As this is essentially an exploratory study, 
two points require clarification from the outset. At this juncture, we have 
focussed solely on associations between SNPs and disease markers, and not on 
haplotypes, which would be possible in the future. As previously stated, we 
have elected not to correct for multiple testing, and we welcome further studies 
in this population to replicate or refute our results. In spite of several significant 
results, our sample size likely precludes definitive conclusions to be made from 
the associations, however they do provide an important guide for further 
research in this population group. 
 
Anti-inflammatory/Tolerance Genes 
IL-10 is a multifunctional cytokine that has potent anti-inflammatory activity 
on a variety of immune cells (Sabat et al. 2010). Specifically, IL-10 plays an 
important role in both the prevention and limitation of overwhelming immune 
reactions (Sabat et al. 2010). IL-10 also plays an important role in the biology 
of B- and T lymphocytes, perhaps most importantly in the differentiation and 
and function of regulatory T lymphocytes (Moore et al. 2001). Through this 
role, IL-10 is thought to play an important part in the attainment of immune 
tolerance (Moore et al. 2001). 
 
592A>C is a promoter polymorphism in the IL-10 gene which is thought to 
play a role in the rate of IL-10 production (Sohn et al. 2007). We found a role 
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for the A allele in increasing the Odds Ratio (OR) for several skin prick tests, 
especially house dust mite skin prick tests. Sensitization to house dust mite is 
known to be commonly associated with allergic rhinitis and asthma, although 
we found no specific associations with either of these two phenotypes. Our 
results are in keeping with findings from several studies, including several 
meta-analyses. Zheng et. al. (2014) showed an association between the A allele 
and a higher incidence of asthma in a recent  meta-analysis,  but  this  
association  only  reached  statistical  significance in adults and with atopic 
asthma in particular. Nie et. al. (2012) also demonstrated an association 
between the A allele and an increased risk of asthma, again with atopic asthma 
in particular. Sohn et. al. (2007) found that the A allele was observed at a higher 
rate in children with atopic eczema. In contrast, we found that the A allele  was 
associated with a decreased OR of atopic eczema, specifically for a self-
reported history of ever having eczema, and for a history of eczema occurring 
during the preceding year. We postulate that this discrepancy between allele 
effects for  different clinical phenotypes may infer specific gene-gene or gene-
environment interactions with respect to atopic eczema in this population 
group, or that this may be a false positive result. 
The G allele in the SNP 1082A>G showed several significant associations, 
predominantly with decreased OR of several aeroallergen skin prick tests, with 
a personal history of wheezing as well as a personal history of rhinitis, and 
with bronchial hyper-responsiveness. These results are in agreement with 
several published studies. Two recent meta-analyses (Nie et al. 2012; Zheng et 
al. 2014)  both demonstrated an association between AA homozygotes and an 
increased risk of asthma, and another meta-analysis (Hyun et al. 2013) showed 
an association between the G allele and a reduced OR for asthma (although 
this effect was only statistically significant in certain Asian populations, and 
only in adults). Our results indicate a strong association between the G allele 
and protection against aeroallergen sensitization, and it is possible that the G 




IgE-mediated sensitization is a necessary process in the development of many 
allergic diseases. IL-4 and IL-13 are central to the development and 
propagation of allergic inflammation, and share several core functions 
including the induction of  IgE class-switching and goblet cell hyperplasia 
(Kau & Korenblat 2014). Both IL-4 and IL-13 signal through a common 
pathway, and enjoy significant receptor homology (Kabesch et al. 2006). 
In this study, IL-4 589C>T showed significant associations with several 
markers of aeroallergen sensitization, as well as with a personal history of 
wheezing and of having eczema. The C allele was found to reduce the OR of 
having any positive skin prick test, with having any positive aeroallergen skin 
prick test, and with having a positive cockroach skin prick test. This is in 
keeping with several results from the literature, including two recent meta-
analyses (Tang et al. 2014; Zhu et al. 2013), which suggested a recessive effect 
of the C allele being protective against the development of asthma. In our 
study, the T allele was found to increase the OR of a history of ever having 
eczema, and again several meta-analyses have suggested a  role for the T allele 
in the formation of asthma (Yang 2013) and allergic rhinitis (Li et al. 2014) 
respectively. Our results also suggest a heterozygote effect on a personal 
history of ever having wheeze or having wheeze in the preceding year. To our 
knowledge, this specific association has not been previously described in the 
literature, however it is possible that different variations of polymorphisms 
may cause allergic disease in different populations, or result in different 
endotypes. 
We found significant associations between two polymorphisms in the gene 
coding for the IL-4 Receptor (IL4RA), and allergic phenotypes. In this study, 
the C allele of IL4RA 478T>C was associated with an increased OR of ever 
having wheeze. This is in contrast to some of the published literature regarding 
this polymorphism. The T allele has previously been associated with higher 
serum IgE levels and a higher risk of bronchial hyper-responsiveness (Howard 
et al. 2002), whereas a recent meta- analysis (Michel et al. 2010) showed no 
association between this polymorphism and asthma risk. Again, this 
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discrepancy may represent unique features of this  population, or may represent 
an example of the limitations of our study. The A allele of the SNP IL4RA 
551A>G was, in our study, associated with a decreased OR of ever wheezing 
or having wheeze in the last year. Several previous studies have suggested an 
association between the G allele of this polymorphism and increased risk of 
allergic disease. Nie et. al. (2013) suggested, in a recent meta-analysis, that the 
G allele confers an increased risk of asthma in children, and that there was a 
specific association with an increase in atopic asthma risk. Three other meta- 
analyses have also suggested an association between the G allele and increased 
risk of allergic disease, specifically asthma (Huang et al. 2015; Loza & Chang 
2007) and allergic rhinitis (Xu & Zhang 2014), although the association with 
allergic rhinitis was possibly dependent on ethnicity. Other trials, including a 
meta-analysis (Bunyavanich et al. 2011), a systematic review of the literature 
(Murk et al. 2011) and a GWAS (Michel et al. 2010) have found no association 
between this specific polymorphism and risk of allergic disease. The literature 
is thus conflicted, and further research will hopefully shed light on this matter. 
 
An SNP in the IL-13 gene, 130A>G , was associated with several disease 
phenotypes. The T allele was weakly associated with a reduced OR of having 
any positive food skin prick test, although the small numbers of positive skin 
prick tests may make the significance of this result open to question. In 
addition, stronger associations were found between the T allele and an 
increased OR of self-reported allergic rhinitis, and heterozygotes were, 
interestingly, strongly associated with an increased OR of self-reported 
eczema. Although it is difficult to explain why different combinations of 
alleles had quite discrepant effects on various allergic diseases, again this could 
be due to inaccuracies in the self-reporting of allergic rhinitis and eczema 
respectively, or because of unexplained variation in gene-gene or gene-
environment interactions between the two diseases. Several other authors have 
interrogated the relationship between this polymorphism and allergic disease. 
Many have found a relationship between the A allele (equivalent to the T allele 
in this study) and an increased risk of allergic disease (Heinzmann et al. 2000; 
Ying et al. 2013; Graves et al. 2000), whilst others found no relationship 
(Howard et al. 2001; Ziyab et al. 2013), although the latter suggested an 
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epistatic relationship between this SNP and one in the STAT6 gene. This study 
does not provide clarity to the literature regarding this specific polymorphism, 
but possibly suggests that the relationship between IL-13 and allergic disease 
in the Xhosa population is not binary. No other significant associations were 
found between any of our other IL-13 SNPs and  allergic disease. 
A polymorphism in the gene encoding for the STAT6 protein, 2964A>G, was 
significantly associated with a self-reported diagnosis of eczema. The A allele 
demonstrated a small, dominant, protective effect against eczema. This is in 
contrast to a recent article (Lee et al. 2015), which suggested no role for the 
polymorphism in the development of atopic eczema. Other meta-analyses (Zhu 
et al. 2013; Qian et al. 2014) have yielded varying results for the association 
of the polymorphism with asthma, with the former suggesting no role, and the 
latter suggesting a protective effect of the G allele. Further studies in this 
population would be required to  replicate our results before this association 
could be confirmed. 
TH1 Genes 
IL-12 and IFN-γ are both play important roles in the generation of a TH1 
immune response. IL-12 is one of the most important stimuli in directing the 
differentiation  of naïve T cells into TH1 lymphocytes (Leonard & Sur 2003). 
IFN-γ is produced by TH1 lymphocytes (amongst others) and is a suppressor 
of TH2 lymphocytes and their cytokines (Teixeira et al. 2005). 
We found the polymorphism in the IL12B gene, 6408delCTCTAAinsGC, to 
be associated with having any positive skin prick test, although again the small 
number of children with positive food skin prick tests impacts the validity of 
this association. The TTAGAG allele was strongly associated, in a dominant 
model, with an  increased OR of a positive food skin prick test. In contrast, 
TTAGAG decreased the OR of ever having wheeze (recessive model), or of 
self-reported eczema in the last year, although this particular association was 
comparatively weak. The results from the literature for this polymorphism 
have also been quite conflicting. A longitudinal study (Khoo et al. 2004) found 
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no association with asthma, but showed an association between the CTCTAA 
allele (equivalent to the TTAGAG allele in this study) and increased IgE in 
males, and decreased FEV1 in females. Another study (Morahan et al. 2002) 
showed an increased prevalence of both atopic and non-atopic asthma in 
heterozygote children, whilst other studies (Tug et al. 2009; Noguchi et al. 
2001) have showed no association between the polymorphism and asthma or 
allergic rhinitis. 
We did not find any significant associations between polymorphisms in the 
gene for IFN-γ, but in terms of genes coding for the IFN-γ receptor, IFNGR 
156T>C, showed some interesting associations. The C allele was found to be 
associated with reduced serum IgE levels, whilst the T allele showed a strong 
association with having any positive food skin prick test. The effect is not 
quantifiable because all individuals who were homozygous for the C allele had 
negative skin prick tests for all foods under investigation, but it appears to be 
highly significant. 
Other genes 
The gene for the β adrenoceptor showed no associations with any of our 
specific asthma phenotypes, including self-reported asthma or wheeze, serum 
IgE levels or bronchial hyper-responsiveness. However, ADBR2 16G>A was 
associated with having any positive aeroallergen skin prick test. The A allele 
showed a significant increase in the OR for this phenotype. There is no 
published literature on the effect of polymorphisms of the β adrenoceptor on 
aeroallergen sensitization or allergic rhinitis, however this polymorphism has 
been extensively studied in regard  to  asthma phenotypes and serum IgE levels. 
The results have been contradictory and,  on the whole, rather disappointing. 
Only one study has previously looked at associations between polymorphisms 
in this gene and asthma in the Xhosa population, and also found no significant 
associations (Potter et al. 1993). One meta- analysis (Contopoulos-Ioannidis et 
al. 2005) showed no association between either  of the two polymorphisms 
under investigation in this study and the prevalence of asthma or of bronchial 
hyper-responsiveness. The G allele of the ADBR2 16 G>A polymorphism was, 
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however, found to be associated with nocturnal asthma and an increased 
prevalence of severe asthma. Another meta-analysis (Migita et al. 2004) 
showed no association between either of the polymorphisms and asthma 
prevalence or severity, and these results were largely replicated in the most 
recent meta-analysis (Liang et al. 2014) of these polymorphisms to date. More 
recently, attention has been turned to the effect of β adrenoceptor 
polymorphisms and response to β agonist therapy (Israel et al. 2004). This, 
however, was not an endpoint of our study. 
Conclusion 
This is the first trial of its kind in the Xhosa population, and indeed in South 
Africa. Our self-reported symptoms may not have sufficient validity to be 
reliably compared to physician diagnosed allergic illnesses, but our prevalence 
data show general agreement with recent published South African literature. 
As a pilot study of these polymorphisms in this population, our results cannot 
be reliably generalized. Furthermore, the limitations described above render 
interpretation of some of the associations very difficult. Of particular interest 
are the association results involving SNPs in which the self-reported markers 
correlate with more objective end points of allergic sensitization (for example 
IL-10 1082A>G and IL-4 589C>T). With regards to these specific 
polymorphisms, further research in this population would be useful to see 
whether these results can be replicated. With respect to other polymorphisms, 
where our self-reported end-points were inconsistent with more objective 
allergic markers, or out-of-keeping with other international literature, it is very 
difficult to postulate whether these associations are of any relevance. It is 
possible that different polymorphisms contribute to allergic disease in different 
population groups, and because this particular group is so under-studied, it may 
be many years before further light is shed on the clinical relevance of our 
findings. In terms of the broader question of the relevance of race and ethnicity 
on the genetic susceptibility to asthma and allergic disease, our findings are 
unlikely to provide significant concrete evidence. However, we believe that 
this study represents a valuable first step in the evaluation of the relationship 
between genotype and phenotype in the development of allergic disease in the 
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Xhosa population. We eagerly anticipate collaboration with colleagues who 
have performed similar studies in other population groups, who may be able to 
help us ascertain whether there are significant discrepancies in prevelance of 




Bunyavanich, S., Shargorodsky, J. & Celedón, J.C., 2011. A meta-analysis 
of Th2 pathway genetic variants and risk for allergic rhinitis. 
Pediatric Allergy and Immunology, 22(4), pp.378–87. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21309855. 
Contopoulos-Ioannidis, D.G., Manoli, E.N. & Ioannidis, J.P.A., 2005. Meta-
analysis of the association of beta2-adrenergic receptor polymorphisms 
with asthma phenotypes. The Journal of Allergy and Clinical 
Immunology, 115(5), pp.963–72. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0091674905000114. 
den Dunnen, J.T. et al. (in press), 2016. HGVS Recommendations for the 
Description of Sequence Variants: 2016 Update. Human Mutation, 
Available at: http://doi.wiley.com/10.1002/humu.22981. 
den Dunnen, J.T. & Antonarakis, S.E., 2000. Mutation nomenclature 
extensions and suggestions to describe complex mutations: a discussion. 
Human Mutation, 15(1), pp.7–12. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10612815. 
Farcomeni, A., 2008. A review of modern multiple hypothesis testing, 
with particular attention to the false discovery proportion. 
Statistical Methods in Medical Research, 17(4), pp.347–88. 
Available at: http://dx.doi.org/101177/0962280206079046. 
Graves, P.E. et al., 2000. A cluster of seven tightly linked polymorphisms in 
the IL- 13 gene is associated with total serum IgE levels in three 
populations of white children. The Journal of Allergy and Clinical 
Immunology, 105(3), pp.506–513. 
Heinzmann, A. et al., 2000. Genetic variants of IL-13 signalling and human 
asthma and atopy. Human Molecular Genetics, 9(4), pp.549–559. 
Howard, T.D. et al., 2002. Gene-gene interaction in asthma: IL4RA and 
IL13 in a Dutch population with asthma. American Journal of Human 
Genetics, 70(1), pp.230–236. 
Howard, T.D. et al., 2001. Identification and association of 
polymorphisms in the interleukin-13 gene with asthma and atopy in a 
dutch population. American Journal of Respiratory Cell and 
133
Molecular Biology, 25(3), pp.377–384. 
Hsueh, H., Chen, J.J. & Kodell, R.L., 2003. Comparison of methods for 
estimating the number of true null hypotheses in multiplicity testing. 
Journal of Biopharmaceutical Statistics, 13(4), pp.675–89. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/14584715. 
Huang, Z.Y. et al., 2015. Association of the IL-4R Q576R polymorphism 
and asthma in the Chinese Han population: a meta-analysis. Genetics 
and Molecular research, 14(1), pp.2900–11. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25867440. 
Hyun, M.H. et al., 2013. Interleukin-10 Promoter Gene 
Polymorphisms and Susceptibility to Asthma: A Meta-
Analysis. PLoS ONE, 8(1). 
Israel, E. et al., 2004. Use of regularly scheduled albuterol treatment in 
asthma: genotype-stratified, randomised, placebo-controlled cross-
over trial. The Lancet, 364, pp.1505–1512. 
Kabesch, M. et al., 2006. IL-4/IL-13 pathway genetics strongly influence 
serum IgE levels and childhood asthma. The Journal of Allergy and 
Clinical Immunology, 117(2), pp.269–274. 
Kau, A.L. & Korenblat, P.E., 2014. Anti-interleukin 4 and 13 for asthma 
treatment in the era of endotypes. Current Opinion in Allergy and 
Clinical Immunology, 14(6), pp.570–575. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25144263. 
Khoo, S.K. et al., 2004. Associations of the IL12B promoter 
polymorphism in longitudinal data from asthmatic patients 7 to 42 
years of age. The Journal of Allergy and Clinical Immunology, 
113(3), pp.475–481. 
Lee, Y.L. et al., 2015. Association of STAT6 genetic variants with childhood 
atopic dermatitis in Taiwanese population. Journal of Dermatological 
Science, pp.2–8. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0923181115001863. 
Leonard, P. & Sur, S., 2003. Interleukin-12: Potential role in asthma 
therapy. BioDrugs, 17(1), pp.1–7. 
Levin, M. et al., 2012. Ascaris sensitization is associated with aeroallergen 
134
sensitization and airway hyperresponsiveness but not allergic disease 
in urban Africa. The Journal of Allergy and Clinical Immunology, 
130(1), pp.265–267. 
Levin, M.E., Muloiwa, R. & Motala, C., 2011. Associations between asthma 
and bronchial hyper-responsiveness with allergy and atopy phenotypes 
in urban black South African teenagers. South African Medical Journal, 
101(7), pp.472– 476. 
Levin, M.E., Le Souëf, P.N. & Motala, C., 2008. Total IgE in urban 
Black South African teenagers: the influence of atopy and helminth 
infection. Pediatric Allergy and Immunology, 19(5), pp.449–54. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/18221478. 
Li, Z. et al., 2014. Association between promoter polymorphisms of 
interleukin-4 gene and allergic rhinitis risk: a meta-analysis. Journal of 
Huazhong University of Science and Technology [Medical Sciences], 
34(3), pp.306–313. Available at: 
http://link.springer.com/10.1007/s11596-014-1275-3. 
Liang, S.-Q. et al., 2014. Beta-2 Adrenergic Receptor (ADRB2) Gene 
Polymorphisms and the Risk of Asthma: A Meta-Analysis of Case-
Control Studies P. Lavoie, ed. PLoS ONE, 9(8), p.e104488. Available 
at: 
http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/
journal. pone.0104488&representation=PDF [Accessed August 13, 
2015]. 
Loza, M.J. & Chang, B.-L., 2007. Association between Q551R IL4R genetic 
variants and atopic asthma risk demonstrated by meta-analysis. The 
Journal of Allergy and Clinical Immunology, 120(3), pp.578–85. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/17586032. 
Michel, S. et al., 2010. Unifying candidate gene and GWAS Approaches in 
Asthma. PloS one, 5(11), p.e13894. 
Migita, O. et al., 2004. ADRB2 polymorphisms and asthma susceptibility: 
transmission disequilibrium test and meta-analysis. International 
Archives of Allergy and Immunology, 134(2), pp.150–7. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/15153795. 
135
Moore, K.W. et al., 2001. Interleukin -10 and the Interleukin -10 receptor. 
Molecular and Cellular Biology, 1(1), pp.683–765. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11244051. 
Morahan, G. et al., 2002. Association of IL12B promoter 
polymorphism with severity of atopic and non-atopic asthma in 
children. The Lancet, 360(9331), pp.455–459. 
Murk, W. et al., 2011. Attempted replication of 50 reported asthma risk 
genes identifies a SNP in RAD50 as associated with childhood atopic 
asthma. Human Heredity, 71(2), pp.97–105. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21734400. 
Nie, W. et al., 2013. Association between Interleukin-4 Receptor    〈 Chain 
(IL4RA) I50V and Q551R Polymorphisms and Asthma Risk: An 
Update Meta-Analysis. PLoS ONE, 8(7). 
Nie, W. et al., 2012. Interleukin-10 promoter polymorphisms and asthma 
risk: A meta-analysis. Cytokine, 60(3), pp.849–855. Available at: 
http://dx.doi.org/10.1016/j.cyto.2012.08.023. 
Noguchi, E. et al., 2001. Identification of missense mutation in the IL12B 
gene: lack of association between IL12B polymorphisms and asthma 
and allergic rhinitis in the Japanese population. Genes and Immunity, 
2(7), pp.401–403. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11704807\nhttp://www.nature.co
m/gene/ journal/v2/n7/pdf/6363790a.pdf. 
Potter, P.C. et al., 1993. Genetic polymorphism of the beta-2 adrenergic 
receptor in atopic and non-atopic subjects. Clinical and Experimental 
Allergy, 23(10), pp.874–877. 
Qian, X. et al., 2014. Association of STAT6 variants with asthma risk: A 
systematic review and meta-analysis. Human Immunology, 75(8), 
pp.847–853. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0198885914001712. 
Sabat, R. et al., 2010. Biology of interleukin-10. Cytokine and Growth 
Factor Reviews, 21(5), pp.331–344. 
Sherry, S.T. et al., 2001. dbSNP: the NCBI database of genetic variation. 





Sohn, M.H. et al., 2007. Association of interleukin-10 gene promoter 
polymorphism in children with atopic dermatitis. The Journal of 
Pediatrics, 150(1), pp.106–8. Available at: 
http://www.sciencedirect.com/science/article/pii/S0022347606008328. 
Tang, L., Lin, H.G. & Chen, B.F., 2014. Association of IL-4 promoter 
polymorphisms with asthma    : a meta-analysis. Genetics and Molecular 
Research, 13(1), pp.1383–1394. 
Teixeira, L.K. et al., 2005. The role of interferon-gamma on immune and 
allergic responses. Memorias do Instituto Oswaldo Cruz, 100 Suppl 
(December 2004), pp.137–144. 
Tug, E. et al., 2009. Relationship between the IL-12B promoter 
polymorphism and allergic rhinitis, familial asthma, serum total IgE, and 
eosinophil level in asthma patients. Journal of Investigational 
Allergology and Clinical Immunology, 19(1), pp.21–26. 
Xu, Y. & Zhang, J.-X., 2014. Interleukin-4 receptor α-chain polymorphisms 
and susceptibility to allergic rhinitis: a meta-analysis. European 
Archives of Oto- Rhino-Laryngology, 271(8), pp.2205–12. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24337880. 
Yang, H.J., 2013. Association between the interleukin-4 gene C-589T and 
C+33T polymorphisms and asthma risk: a meta-analysis. Archives of 
Medical Research, 44(2), pp.127–135. 
Ying, X.J. et al., 2013. Association of interleukin-13 SNP rs20541 with 
allergic rhinitis risk: A meta-analysis. Gene, 521(2), pp.222–226. 
Available at: http://dx.doi.org/10.1016/j.gene.2013.03.088. 
Zar, H.J. et al., 2007. The changing prevalence of asthma, allergic rhinitis 
and atopic eczema in African adolescents from 1995 to 2002. Pediatric 
Allergy and Immunology, 18(7), pp.560–565. 
Zheng, X.Y. et al., 2014. Interleukin-10 promoter 1082/-819/-592 
polymorphisms are associated with asthma susceptibility in Asians and 
atopic asthma: A meta- analysis. Lung, 192(1), pp.65–73. 
Zhu, L. et al., 2013. The Correlation Analysis of Two Common 
137
Polymorphisms in STAT6 Gene and the Risk of Asthma: A Meta-
Analysis. PLoS ONE, 8(7). 
Zhu, N. et al., 2013. Association between the polymorphisms of 
interleukin-4, the interleukin-4 receptor gene and asthma. Chinese 
Medical Journal, 126(15), pp.2943–51. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23924473. 
Ziyab, A.H. et al., 2013. Interactive effect of STAT6 and IL13 gene 
polymorphisms on eczema status: results from a longitudinal and a 
cross-sectional study. BMC Medical Genetics, 14, p.67. 
138
